Biodegradable Bone Implants as a New Hope to Reduce Device-Associated Infections—A Systematic Review

José C. C. Paiva 1, Luís Oliveira 2, Maria Fátima Vaz 3,4 and Sofia Costa-de-Oliveira 5,6,*

1 Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2 DPS—Product Systems Development, INEGI—Institute of Science and Innovation in Mechanical and Industrial Engineering, 4200-465 Porto, Portugal
3 IDMEC—Instituto Superior Técnico, Universidade de Lisboa, 1499-002 Lisboa, Portugal
4 Departamento de Engenharia Mecánica, Instituto Superior Técnico, Universidade de Lisboa, 1499-002 Lisboa, Portugal
5 Division of Microbiology, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
6 Center for Health Technology and Services Research—CINTESIS@RISE, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
* Correspondence: sqco@med.up.pt

Abstract: Bone fractures often require fixation devices that frequently need to be surgically removed. These temporary implants and procedures leave the patient more prone to developing medical device-associated infections, and osteomyelitis associated with trauma is a challenging complication for orthopedists. In recent years, biodegradable materials have gained great importance as temporary medical implant devices, avoiding removal surgery. The purpose of this systematic review was to revise the literature regarding the use of biodegradable bone implants in fracture healing and its impact on the reduction of implant-associated infections. The systematic review followed the PRISMA guidelines and was conducted by searching published studies regarding the in vivo use of biodegradable bone fixation implants and its antibacterial activity. From a total of 667 references, 23 studies were included based on inclusion and exclusion criteria. Biodegradable orthopedic implants of Mg-Cu, Mg-Zn, and Zn-Ag have shown antibacterial activity, especially in reducing infection burden by MRSA strains in vivo osteomyelitis models. Their ability to prevent and tackle implant-associated infections and to gradually degrade inside the body reduces the need for a second surgery for implant removal, with expectable gains regarding patients’ comfort. Further in vivo studies are mandatory to evaluate the efficiency of these antibacterial biodegradable materials.

Keywords: bone temporary implant; antibacterial biomaterial; fixation devices; implant-associated infection; biodegradable implant; fractures

1. Introduction

1.1. Infection

Osteomyelitis is a bone and marrow infection that can be developed due to a bloodstream infection or is usually secondary to a contiguous focus of infection in the context of trauma, reconstructive bone surgery or implant insertion [1,2]. Injuries such as open fractures can cause microorganisms to enter the body and infect the bone [2]. The incidence of osteomyelitis resulting from orthopedic trauma ranges from 5% to 10%, depending on the injury location and severity, type of fracture [3,4], the extent of collateral injuries, host’s physiological response and other risk factors, including male gender, smoking habits or diabetes mellitus [5–10]. The infection rate after internal fixation shifts between 1 and 2% on close fractures, rising to 30% on open fractures [11]. The two principal factors responsible for implant-associated infections are the immune ability at the interface between the implant and the surrounding tissues [12,13], which can be compromised after surgery [14].
and biofilm formation, also associated with 80% of all chronic infections, according to the
National Institutes of Health [15].

A biofilm is a conglomerate of bacteria held together and protected by a self-produced extracellular polymeric substance (EPS) matrix, composed of proteins, polysaccharides and extracellular DNA. The colonization of the bone or the implant occurs through bacteria adhesion and attachment. Then bacteria cells bind to each other and the extracellular matrix, maintaining biofilm integrity and mediating their communication through biochemical signals, increasing their resistance, namely, to available antibiotics, environmental stress and host immune response [16,17].

In general, *Staphylococcus aureus* and coagulase-negative staphylococci (CoNS) are responsible for up to two-thirds of all fracture-related infections, with *S. aureus* being the most prevalent single pathogen [18,19]. Other less common pathogens include members of the Enterobacterales family, *Pseudomonas aeruginosa*, *Streptococcus spp.* and anaerobes [18–20]. Polymicrobial infections can reach 30% of incidence and mainly occur in patients with open-fracture patients [20].

Multiple strains have developed high levels of antibiotic resistance [21,22], including MRSA, complicating the treatment of implant-associated infections and leading to poorer outcomes [23,24]. Although antibiotics are the first-line treatment for bacterial infections [25], sole treatment will frequently fail [26], as the inflammatory process leads to compression of vascular bone channels, causing ischemia and thus low penetration of antimicrobials into the inflamed bone tissue [27,28]. Therefore, tackling implant-associated infections usually requires a deeper and more invasive approach consisting of a secondary surgery involving irrigation, debridement and use of antibiotics as well, or even exchange or complete removal of the implant when necessary [29,30]. Besides being difficult to treat, implant-associated infections may represent a tremendous burden not just for patients receiving bone implants [31,32], considering the subsequent risk of a generalized infection [33], greater morbidity and psychological costs [34,35], but also from financial and societal points of view [25]. Bearing in mind how easily biofilms can thrive [33] and how difficult it is to treat implant-associated infections, the focus has been shifting towards the production of implants with intrinsic antibacterial properties to prevent implant-associated infections from arising [25].

1.2. Implants

All over the world, year after year, millions of people improve their lives through surgical procedures involving medical device implantation [29]. The implantable materials shall fulfill some requisites so that the surgery goals can be met, such as biocompatibility [36], not eliciting negative biological responses, and maintenance of an adequate function altogether [37,38]. Biomaterials used in medical implants are meant to improve their features [39,40]. The rising demand for implants and biomaterials across the globe, allied to incessant development in the field of Material Science and Engineering, has been responsible for great leaps forward in the medical implants field and their introduction into medical practice [29,36]. Not only in orthopedics but implants are also being used in other medical fields, whether in the form of catheters, pacemakers, cardiovascular stents, medication reservoirs, monitoring body functions, providing support and stimulating organs and tissues or even as tools for cosmetic or dental purposes [36,41–43]. The biomaterials used in implantable devices comprise metals, ceramics and polymers, based on metallic, ionic and covalent bonds, respectively [29], metals being the most preferred materials [44].

Metals have been famous for their mechanical strength for a long time. They have been used since the 1890s for orthopedic applications, incorporating high load-bearing implants. Stainless steel, titanium and cobalt-chromium alloys have dominated the market as orthopedic implant materials [44,45]. However, magnesium, a safely biodegradable in vivo and lightweight material, has recently been emerging as a good alternative due to its special properties, especially when combined with other elements such as calcium, zinc,
manganese, strontium, tin and silver, which have been introduced to reduce corrosion and increase strength [36].

Polymers have been used in medical procedures as part of internal fixation devices [46], such as bone plates, screws and intramedullary pins [47]. They have overcome metals in some intrinsic properties, such as elasticity, flexibility, longevity and bio-inertness [48]. Among synthetic biodegradable polymers, the most widely employed have been polyglycolide (PGA), polylactide (PLA) and PCL [49,50], as they have good biocompatibility and are safely eliminated by metabolic pathways [51].

Ceramics are brittle materials, so they have limitations if used for load-bearing purposes. However, they can be useful while fixing or replacing hard connective tissues, including bone [38,52]. Calcium hydroxyapatite, besides being the bone inorganic phase’s main component [29], stands out among bioactive ceramics as a convenient coating for dental and orthopedic metal implants ensuring that their fixation in bone lasts longer [53].

Conventional non-absorbable or non-biodegradable implants also have some inherent disadvantages, including higher surgical risk and inconvenience and discomfort for patients taking into account the need for reoperations when implant removal is needed [46]. Implant failure may be due to mechanical factors, stress–strain imbalances, implant migration and wear debris, or biological reasons, such as foreign body reactions or bacterial infections [54–56]. According to the Center for Disease Control, the number of deaths caused by infections and antibiotic-resistant bacteria will outrun the fatalities from all kinds of cancers by 2050; hence, the development of medical devices comprising materials and properties capable of curbing bacteria functions is compelling [29].

Biodegradable or bioabsorbable implants have been revolutionizing orthopedic surgery, as long as they can be gradually replaced by new forming tissue, restoring the normal bone functions with no need to be removed in a second surgery [47]. Additionally, they can have integrated drugs or growth factors to promote healing and prevent infections [57–59]. However, since these devices are “programmed to disappear” inside the body and lose their biomechanical strength, any mismatch between the implant absorption and the healing process may have adverse results, including implant failure, fibrosis, or inflammatory reactions [60–63]. The implant absorption is not a guarantee of efficacy and once the absorption has started, it can be difficult to remove the device [64]. The biodegradable implants can only be employed in low load-bearing applications.

Herein, we systematically review the literature regarding the use of biodegradable bone implants in fracture healing and its impact on the reduction of implant-associated infections.

2. Methods

The systematic review was carried out in strict accordance with the Cochrane Handbook for Systematic Reviews of Interventions [65], and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [66] checklist of the review was followed (Table S1 in Supplementary Materials).

2.1. Data Sources and Search Strategy

The electronic bibliographic databases of PubMed, Scopus and Web of Science were searched using a combination of MeSH terms and/or keywords in all fields of the research studies, regarding broad domains, such as osteomyelitis, bone fixation device, infection and biodegradable bone implant. For PubMed search, the following query was used: (Bone* OR “Bone and Bones”[Mesh]) AND (“Bone Infection*” OR Osteomyelitis OR “Implant-related Infection*” OR “Implant-associated Infection*” OR “Device-related Infection*” OR “Device-associated Infection*” OR “Bone Diseases, Infectious”[Mesh] OR biofilm*) AND (absorbable OR biodegradable OR bioabsorbable OR “Absorbable Implants”[Mesh] OR “Bioabsorbable Implant*” OR “Biodegradable Implant*” OR “Materials Testing”[Mesh]) AND (Device* OR Implant* OR “Bone-Implant Interface”[Mesh] OR “Fracture Fixation”[Mesh] OR “Osseointegration” OR “Prostheses and Implants”[Mesh] OR “Orthopedic Fixation Devices”[Mesh] OR “Bone Substitutes”[Mesh]). Regarding Scopus
and Web of Science the used query was: (Bone* OR “Bone and Bones”) AND (“Bone Infection*” OR Osteomyelitis OR “Implant-related Infection*” OR “Implant-associated Infection*” OR “Device-related Infection*” OR “Device-associated Infection*” OR “Bone Diseases, Infectious” OR biofilm*) AND (absorbable OR biodegradable OR bioabsorbable OR “Absorbable Implants” OR “Bioabsorbable Implant*” OR “Biodegradable Implant*” OR “Materials Testing”) AND (Device* OR Implant* OR “Bone-Implant Interface” OR “Fracture Fixation” OR “Osseointegration” OR “Prostheses and Implants” OR “Orthopedic Fixation Devices” OR “Bone Substitutes”). Studies were selected and screened from January 2014 up to November 2021. The search included all publication types except reviews or systematic reviews and no language restrictions were applied.

2.2. Study Eligibility Criteria

Studies were included in this review if they met the following criteria: (1) in vivo or human or simultaneously both in vitro and in vivo studies, (2) full biodegradable implants/devices or scaffolds in bone fixation and its impact on infection prevention, (3) in vivo studies comparing biodegradable versus non-biodegradable implants regarding bone infection, (4) in vivo studies testing biodegradable implants and its antibacterial activity and (5) in vivo studies including microbiology analysis.

The exclusion criteria were: (1) studies conducted only in vitro, (2) studies not addressing bone infection and implant biodegradability; (3) biodegradable coatings on the surface of non-biodegradable implants; (4) studies that have no reference to implant applicability; (5) studies regarding only antibiotic delivery systems; (6) studies where no antibacterial testing or microbiology analysis was performed; (7) devices outside the scope of orthopedics; (8) reviews, systematic reviews, patents and grey literature.

2.3. Data Extraction and Search Results

A total of 727 references were obtained in the three databases used: 387 from PubMed, 256 from Scopus and 84 from Web of Science. The extracted studies were uploaded to Rayyan software [67] for duplicate removal, quality assessment and further selection. A screening of the title, abstract and full text was performed and guided based on inclusion and exclusion criteria by two independent reviewers in a blinded standardized manner. Twenty-three studies were included in the systematic review (Figure 1). The outline of this systematic review is presented in Figure 2.

2.4. Assessment of Risk of Bias

To evaluate the risk of bias in the studies included in this review, the Office of Health Assessment and Translation Risk of Bias Rating Tool for Human and Animal studies were used. A 4-point scale was used to grade the potential source of bias as definitely low (++), probably low (+), probably high (−) or not reported (NR) and definitely high (−) (Table S2 in Supplementary Materials).
Figure 1. PRISMA flow chart representing the systematic identification of studies search via databases and registers.

Figure 2. Systematic review outline strategy.
3. Results

3.1. Biomaterials

The implants used in the selected studies are present in Tables 1 and 2. Different types and shapes, such as nails [68–70], screws [70–72], rods [73–77], wires [78], pellets [79], discs [80] and cylindrical or cubic scaffolds [81–87], were tested. A variety of materials were used, metals, polymers and calcium phosphates being among the most employed.

Mg was the most used metal, either alone in a pure state [72,74], or combined with other metals [69,73,74,76–78,88]. One study also reported a combination with a coating of UMAO-phytic acid [68]. Zn immediately followed Mg as the second most used metal [70,73,75–78]. Every study whose implants had a metallic composition incorporated at least one of these two components, and nearly half presented the combination of Mg and Zn in a Mg-Zn alloy [73,76–78]. The third most used metal was Cu, incorporated in Mg-Cu [69] and Zn-Cu [75] alloys. Others were employed less frequently, such as Ag [70], Ga and Sr [74], Al [73,76], Sn [77], Nd and Zr [88]. Most of these articles were comparative studies, using titanium implants as a control [69,70,72–75,77,78,88].

Apart from metallic devices, other studies used implants resulting from the mixture of different biodegradable polymers and calcium phosphates [71,79,81,83–87,89] or bone-like substitutes [82,85] as backbone materials, which could also incorporate macromolecules [81,89], nanoparticles [84] and silica [87]. Three implants followed a different pattern: two contained only a polymer within their core [80,85], and the other one was polymer-free [84]. The most used materials were poly-lactic acid-based polymers, PLGA, PLLA and PLDLA, as well as PU. Other polymers, such as PEG, PCL and Poly(3-hydroxybutyrate) (P3HB), were also employed. Among calcium phosphates, hydroxyapatite and nano-hydroxyapatite were the most prevalent.

3.2. Antimicrobial Agents

Some implants got their antibacterial properties conferred through several processes involving not just antibiotic impregnation, but also different combinations of antibiotics, metals, ions, polymers, salts, silica, hydroxyapatite or antimicrobial peptides, generally to produce device coatings or loadings (Tables 1–3). In other studies, implants contained materials within their core with intrinsic bactericidal activity, especially metallic elements (Table 2).

Vancomycin was the most widely used antibiotic, either impregnating the implant [85], combined with PLGA to cover [82] or incorporate [89] different scaffolds, or even combined with silica [83] for coating production purposes. Likewise, other antibiotics, such as imipenem/cilastatina (Tienam) [79] or a combination of gentamicin and clindamycin [81], were also used in scaffolds. Additional coatings were created by mixing levofloxacin with gold [90] and ciprofloxacin with PLLA and NaCl [91] (Table 2).

Apart from antibiotics, silver phosphate and silver nanoparticles were incorporated into scaffolds in two studies [84,86] and two additional coatings involving metals were produced through the combination of Cu with UMAO-phytic acid [68] and selenium with calcium phosphate [80]. Finally, a coating of PSI10, an antimicrobial peptide, combined with hydroxyapatite, was also investigated [76].

Taking into consideration the metallic implants, Mg and Zn were the most used ones, alloyed with each other and with other metals, boosting the antibacterial activity of the implants they integrated (Table 2).
### Table 1. Implant type, production process and composition.

| Ref. | Implant Type | Production Process | Control | Polymers | Calcium Phosfates | Bone | Macromolecules | Silica | Nanoparticles |
|------|--------------|--------------------|---------|----------|-------------------|------|----------------|--------|---------------|
|      |              |                    |         |          | PLGA              | PLLA| PLDLA| PU | PCL | P3HB | BCP | β-TCP | HA | n-HA | BHA | DPB | DBBP | CMC | PAA | MSN | RGO |
| [81] | Cylindrical  | Melt-blending, powder production and moulding | x x x x | x x x x | x x x x x | x x | x x | x x | x x | x x |
| [89] | Scaffold      | Emulsification-solvent evaporation; homogeneous method using an in-situ diffusion control system | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [82] | Cylindrical  | Bovine cancellous bone deproteinization; 3D Printing using Electrospinning | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [91] | Cylindrical  | Injection molding, hot melt dip coating | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [83] | Scaffold      | 3D printing using Electrospinning, aqueous precipitation of PLLA | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [71] | Screw         | Mold injection process | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [66] | Scaffold      | In situ foaming (method), Freeze-drying, mold die production process | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [85] | Scaffold      | 3D printed Electrospun PU fibers | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [87] | Scaffold      | 3D printing of in-situ deposition of foams | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [80] | Disc          | 3D Printing, in situ precipitation | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [79] | Pellets       | Bacterial biomass (bacterium Ralstonia eutropha B5786); Granulation, cold molding and water leaching | x x | x x x x | x x x x | x x | x x | x x | x x | x x |
| [84] | Scaffold      | 3D Precipitation in aqueous solution | x x | x x x x | x x x x | x x | x x | x x | x x | x x |

**Abbreviations:** PLGA—Poly(DL-lactic acid-co-glycolic acid), P3HB—Poly(3-hydroxybutyrate), BCP—Bifasic-calcium phosphate, β-TCP—β-Tricalcium phosphate, n-HA—Nanohydroxyapatite, BHA—Bone-like hydroxyapatite/poly(amino acid), Bio-Oss—Bovine porous bone mineral xenograft, DPB—Deproteinized bovine cancellous bone, DBBP—Decellularized bovine bone particles, CMC—Carboxymethyl cellulose, PAA—Poly(amino acid), containing 6-aminocaproic acid, glycine, L-alanine, L-phenylalanine, L-proline and L-lysine, MSN—Mesoporous silica nanoparticles, RGO—Reduced graphene oxide.
Table 2. Implant type, production process and composition.

| Ref. | Implant Type | Production Process | Control | Metals |
|------|--------------|--------------------|---------|--------|
| [68] | Nail         | UMAO, Phytic acid conversion coating, electroless copper plating | x       |        |
| [72] | Screw        | Additive Manufacturing, laser sintering, cold rolling | Ti x    |        |
| [74] | Rod          | Micro-alloying, powder metallurgy | cpTi x x |        |
| [69] | Nail         | Metallurgical casting | Ti x x |        |
| [73] | Rod          | Powder metallurgy | cpTi x x | x      |
| [73] | Rod          | Solid-phase synthesis | x x x |        |
| [77] | Rod          | Powder Metalurgy, localized melting of Powders | Ti x x |        |
| [88] | Cylinder     | Additive manufacturing; selective laser melting | Ti x x | x x   |
| [78] | Wire         | Powder metallurgy | Ti x x |        |
| [75] | Rod          | Extrusion of heat-treated materials | Ti x x |        |
| [70] | Screw        | Extrusion of heat-treated materials | Ti x x |        |

Abbreviations: Mg—Magnesium, Zn—Zinc, Cu—Copper, Ag—Silver, Ga—Gallium, Sr—Strontium, Al—Aluminum, Sn—Tin, Nd—Neodymium, Zr—Zirconium.
Table 3. Analyses of implants’ biodegradability, osteointegration and antibacterial properties: in vitro and in vivo studies.

| Ref. | Implant Type (Scaffold, Screw, …) | Coating/Imregnated Antibiotics | Study Design/Type of Study | Surgical Site | Microorganisms | Previous Established Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antimicrobial Admin. | Sacrifice Timepoint/Follow-Up Time after Surgery | Bisabortion/Biodegradability | Osteointegration | Microbiology analysis In Vivo | Microbiology Analysis In Vivo | Outcome |
|------|---------------------------------|--------------------------------|---------------------------|--------------|----------------|--------------------------------|--------------------------------|--------------------------------|---------------------------------|-----------------------------|---------------|-----------------------------|-----------------------------|----------|
| [81] | Cylindrical Scaffold            | None                           | In vivo                   | Femoral condyle | S. aureus (F2789) | At surgery                        | No                             | No                            | 2 weeks                         | No                          | No                         | Presence of S. aureus (F2789) | -         | The scaffold impregnated with 4% Gentamicin + 2.5% Clindamycin was effective at preventing S. aureus infection, whilst supporting a significant amount of new bone growth in a 13 week period. |
| [81] |                               |                                |                           | None          | None             |                                 | No                             | No                            | 2 weeks                         | No                          | No                         | None                       | None                  | -         | No bacteria found |
| [89] | Scaffold granules              | None                           | In vivo                   | Tibia metaphysis | S. aureus          |                                 | No                             | No                            | 4 weeks                         | -                          | -                          | -                          | -         | -         | Clearance of the infection |
|       |                                 |                                |                           | None          | None             |                                 | Prior to surgery                | No                            | 4 weeks                         | -                          | -                          | -                          | -         | -         | -         | The V-BHA/PAA scaffold promoted infection clearance and was gradually replaced by new forming bone during degradation. The scaffold and bone almost integrated with one another by the end of the experiment, and the bone defect underwent complete healing. |
| [71] | Screw                          | None                           | Case series              | Tibia proxi-imal tunnel | S. aureus          |                                 | No                             | Yes                           | 2–4 years                       | No                          | No                         | Prevention of S. aureus infection | -         | No purulent discharge was observed |
|       |                                 |                                |                           | None          | S. aureus        |                                 | No                             | No                            | 4, 6 & 12 weeks                  | No                          | No                         | -                          | -         | -         | -         | The soft-tissue reaction led to extrusion of still intact biodegradable screws. |
Table 3. Cont.

| Ref. | Implant Type (Scaffold, Screw, ... ) | Coating/Impregnated Antibiotics | Study Design/Type of Study | Surgical Site | Microorganisms | Previous Established Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antimicrobial Admin. | Sacrifice Timepoint/Follow-Up Time after Surgery | Bioabsorption/Biodegradability | Osteointegration | Microbiology Analysis In Vivo | Microbiology Analysis In Vivo | Outcome |
|------|-----------------------------------|---------------------------------|---------------------------|---------------|----------------|-------------------------------|----------------------------------------|---------------------------------|-----------------------------------------------|-------------------------------|----------------|-----------------------------|-----------------------------|---------|
| [86] | Scaffold None                      |                                | In vivo                   | Tibial peroneal metaphysis | S. aureus (ATCC 29213) | Yes Prior to surgery (4 weeks) | No                                      |                                  | 3 weeks -                                          | Yes                            |                  | Infection progression        |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 6 weeks Partially                  | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 12 weeks Yes                        |                  |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 3 weeks Very low                    | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 6 weeks Partially                  | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 12 weeks Yes                        |                  |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 3 weeks -                                          | No                             |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 6 weeks -                                          | No                             |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 12 weeks Yes                        |                  |                  |                              |                            |         |
| [83] | Scaffold None(Blank control group) |                                | In vivo                   | Femoral diaphysis          | MRSA (ATCC 43300) | Yes Prior to surgery (1 week) | No                                      |                                  | 1 month No                           | No                             |                  | Severe infection            |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 3 months -                                          |                  |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 1 month Mostly                      | -                              |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 3 months Yes                         | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 1 month Mostly                      | -                              |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 3 months Yes                         | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 1 month Mostly                      | -                              |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 3 months Yes                         | Yes                            |                  |                              |                            |         |
| [85] | Scaffold None                      |                                | In vivo                   | Radius middle shaft        | S. aureus (UAMS-1) | Yes At surgery No            | No                                      |                                  | 4 weeks Yes                          | No                             |                  | Presence of S. aureus         |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 8 weeks No                           | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 12 weeks Yes                         | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 4 weeks -                                          | No                             |                  | No signs of infection         |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 8 weeks -                                          | Yes                            |                  |                              |                            |         |
|      |                                    |                                |                           |                            |                |                              |                                        |                                  | 12 weeks No                          | Yes                            |                  |                              |                            |         |

The nanocomposite scaffold with 15 wt% drug can undergo degradation and simultaneously control infection, even though 100% bacterial elimination was not observed. However, it showed higher antibacterial efficiency than the 5 wt% Vancomycin scaffolds.
| Ref. | Implant Type (Scaffold, Screw, …) | Coating/Impregnated Antibiotics | Study Design/Type of Study | Surgical Site | Microorganisms | Previous Established Infection | Implantation/Seeding of Microorganisms | Prophylactic Antibacterial Admin. | Sacrifice Time/Post-Op Time Follow-Up Time after Surgery | Resorption/Biodegradability | Osteointegration | Microbiology analysis In Vitro | Microbiology Analysis In Vivo | Outcome |
|------|---------------------------------|---------------------------------|---------------------------|--------------|----------------|-------------------------------|-------------------------------------|-------------------------------|-----------------------------------|---------------------------|----------------|---------------------------------|-----------------------------|----------|
| [87] | Cuboid Scaffold                  | Gold + Levofloxacin 1 mg        | In vivo                   | Tibia medullary cavity | S. aureus (ATCC 25923) | Yes                           | Prior to surgery (4 weeks)            | -                            | 1 week                           | No                        | -              | -                               | -              | -       |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 3 weeks                           | Low                       | -              | -                               | -              | -       |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 6 weeks                           | -                        | -              | -                               | -              | -       |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 12 weeks                          | Partially                | Yes             | No signs of infection            | -              | -       |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 1 week                            | No                       | -              | No                               | -              | -       |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 3 weeks                           | No                       | -              | No signs of infection            | -              | -       |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 6 weeks                           | No                       | -              | No signs of infection            | -              | -       |
|      | None/Blank control group         | -                               | In vivo                   | Tibia medullary cavity | S. aureus (ATCC 25923) | Yes | Prior to surgery (4 weeks) | - | 1 week | No | No | - | - | Infection progression |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 3 weeks                           | - | No | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 6 weeks                           | - | No | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 12 weeks                          | - | No | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 1 week                            | - | No | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 3 weeks                           | No | - | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 6 weeks                           | No | - | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 12 weeks                          | Yes | - | No signs of infection            | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 1 week                            | No | - | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 3 weeks                           | No | - | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 6 weeks                           | No | - | - | - |
|      |                                 |                                 |                           |              |                |                               |                                     |                               | 12 weeks                          | No | No | No | - |
|      | Cylindrical Scaffold            | PLGA + Vancomycin               | In vivo                   | Radius diaphysis | Yes | At surgery | Vancomycin | 8 weeks | Partially | Partially | - | - | Lower bacterial load |
|      | PLGA                            | In vivo                         |                          |              |                |                               |                                     |                               | No | No | No | - | - |
| [82] | DPB                             | PLGA + Vancomycin               | In vivo                   | Tibia medullary cavity | MRSA (ATCC 25923) | Yes | Along 30 days | - | Absorbent effect maintained for 28 days | - | No antibacterial effect | - | - | - |
|      | PLGA                            | In vivo                         |                          |              |                |                               |                                     |                               | No | No | No | - | - |

5 mg Lev® MEGs/n-HA/PU began to degrade 12 weeks after implantation. Prior to 12 weeks, the integrity of the material structure provided mechanical support for bone repair and its degradation contributed to new bone formation. Infection signs were successfully curbed.
| Ref. | Implant Type (Scaffold, Screw, ... ) | Coating/Impregnated Antibiotics | Study Design/Type of Study | Surgical Site | Microorganisms | Previous Established Infection | Incubation/Seeding of Microorganisms | Prophylactic/Antimicrobial Admin. | Sacrifice/Timepoint/Follow-Up Time after Surgery | Resorption/Biodegradability | Osteointegration | Microbiology analysis In Vitro | Microbiology Analysis In Vivo | Outcome |
|------|-----------------------------------|---------------------------------|---------------------------|---------------|----------------|-------------------------------|-------------------------------------|--------------------------------|---------------------------------|---------------------------|--------------|-----------------------------|-----------------------------|----------|---------|
| [91] | Cylindrical Implantable matrice | PLLA [NPC] + Ciprofloxacin | In vivo | Femur | No | No | No | No | 40 days | No | No | No | No | No signs of infection |
|       | PLLA/NaCl40% (SPC) + Ciprofloxacin | In vivo | Cylindrical Implantable matrice | PLLA/NaCl40% (IPC) + Ciprofloxacin | In vivo | - | S. aureus, Bacillus subtilis, Micrococcus luteus, E. coli, P. aeruginosa | - | Yes | Along 40 days | Partially | - |
|       | PLLA/NaCl40% (IPC) + Ciprofloxacin | In vivo | UMAO-phytic acid-Cu-0 | In vivo | Mandible | No | No | No | No | 2 weeks | No | 4 weeks | In between | Partially | - |
|       | PLLA/NaCl40% (IPC) + Ciprofloxacin | In vivo | UMAO-phytic acid-Cu-3 | In vivo | Mandible | No | No | No | No | 2 weeks | No | 4 weeks | Lower | Yes | - |
|       | PLLA/NaCl40% (IPC) + Ciprofloxacin | In vivo | UMAO-phytic acid | In vitro | - | S. aureus (ATCC 6538) | - | Yes | - | 24 h | - | - | No antibacterial activity |
|       | UMAO-phytic acid-Cu-0 | In vitro | UMAO-phytic acid-Cu-3 | In vitro | - | S. aureus (ATCC 6538), coli (ATCC 2922) | - | Yes | - | 24 h | - | - | Low antimicrobial activity |
|       | UMAO-phytic acid-Cu-5 | In vitro | UMAO-phytic acid-Cu-3 | In vitro | - | S. aureus (ATCC 6538), coli (ATCC 2922) | - | Yes | - | 24 h | - | - | Antibacterial rate >80% |
|       | UMAO-phytic acid-Cu-3 | In vitro | UMAO-phytic acid-Cu-3 | In vitro | - | S. aureus (ATCC 6538), coli (ATCC 2922) | - | Yes | - | 24 h | - | - | Antibacterial rate >90% |

PLL A based CPX-IMs with porous surface are compatible with surrounding bone and muscle tissues and can sustain adequate antibiotic concentrations within defected area, preventing infection. Nonetheless, CPX-IMs of larger pore size showed more successful osteointegration than the smaller pore size.

The introduction of Cu2+ in the copper plating coating effectively inhibited the growth and propagation of the bacteria, and the antibacterial rate was proportional to the Cu content. (However, the coating Cu-5 inhibited cell growth in vitro and was not evaluated in vivo.) Finally, UMAO-phytic acid-Cu 3min implants slow down the in vivo corrosion rate, promote antimicrobial activity and bone growth.
Table 3. Cont.

| Ref. | Implant Type (Scaffold, Screw, …) | Coating/Impregnated Antibiotics | Study Design/Type of Study | Surgical Site | Microorganisms | Previous Established Infection | Inoculation/Seeding of Microorganisms | Prophylactic/Antimicrobial Admin. | Sacrifice-Timepoint/Follow-Up Time after Surgery | Biodegradation/Osteointegration | Microbiology Analysis In Vitro | Microbiology Analysis In Vivo | Outcome |
|------|-----------------------------------|---------------------------------|---------------------------|---------------|-----------------|-------------------------------|-------------------------------------|-------------------------------|-----------------------------------------------|-----------------------------|-----------------------------|-----------------------------|---------|
| [80] | Disc                              | CaP                             | In vitro                  | Skull         | -               | No                            | No                                 | -                             | 8 weeks                         | Partially                    | Yes                        | -                          | -       |
|      |                                   | Se-CaP                          |                           |               |                 |                               |                                     |                               |                                | Partially                    | Higher                     | -                          | -       |
|      |                                   | CaP                             |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | Se-CaP                          |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
| [84] | None                              | -                               | In vitro                  | Radius middle shaft | MRSA       | Prior to implantation (10 days) | Yes                                 | No                            | 4, 8 & 12 weeks                  | No                          | Low                        | -                          | -       |
|      |                                   | None                            |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | 4% AgNP                         |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | 1%/2%/4%/8% AgNP                |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
| [76] | Rod                               | None                            | In vitro                  | Femoral condyle | -            | No                            | No                                 | Penicillin postop               | 4, 8 & 12 weeks                  | No                          | Yes                        | -                          | -       |
|      |                                   | HA                              |                           |               |                 |                               |                                     |                               |                                |                             |                           | To some extent              | -       |
|      |                                   | HA                               |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | HA                              |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | PS10                            |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | HA                              |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | HA                              |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
|      |                                   | None                            |                           |               |                 |                               |                                     |                               |                                |                             |                           | -                          | -       |
3.3. Implant Antibacterial Properties, Biodegradability, Osteointegration: In Vitro and In Vivo Studies

3.3.1. Microbiology Analysis

Bacterial species included in the in vitro and in vivo studies are displayed in Table 3. *S. aureus* was the most tested strain, including MRSA [82–84,89].

Regarding in vivo studies, to pre-establish infection in animal models, the majority of the animals underwent inoculation of bacteria either at the moment of the implantation surgery [81,82,85] or before the surgery [83,86,87,89], generally some few weeks previously. Dumlao et al. presented two human case studies reporting a PLDLA bioabsorbable screw extrusion and *Pseudomonas aeruginosa* tibial tunnel infection after 2 and 4 years of anterior cruciate ligament reconstruction [71]. *P. aeruginosa* that grow from patients’ tissue samples has shown to be susceptible to all antimicrobial drugs tested [71].

Concerning the in vivo studies complemented by in vitro relevant data on microbiology analysis, only one study reported previously established infection in animals before implantation (10 days) [84]. Moreover, one article evaluated the presence of infection in vivo, even though no animals had been intentionally infected [91]. The remaining studies did not address infection in vivo [68,76,80]. Finally, each one of the referred studies underwent further detailed microbiology analysis in vitro [68,76,80,84,91].

To assess the implants’ bacterial load and their effectiveness in preventing biofilm formation, the methods to evaluate the presence of bacteria along and at the end of the in vivo experiments were tissue culture [71,82,83], both tissue sample and blood culture [81], gross observation/appearance of bone defect [89,91], gross bone pathology [87], culture of bone and degrading scaffold [85], radiological evaluation through X-ray imaging and counting of white blood cells on venous blood analysis [86] and histopathological findings to exclude neutrophilic infiltrates and abscess formation [91]. Conversely, in vitro antibacterial analyses were obtained through the determination of inhibition diameter on agar plate culture [84,91], the growth of colonies on different films surfaces [68], crystal violet staining of biofilms formed 48 h after scaffold immersion on bacterial suspension [80], and through a liquid growth inhibition assay [76].

In in vivo experiments, the association of biodegradable implants with Ag nanoparticles [86] or with antibiotics such as gentamicin and clindamycin [81] and vancomycin [85] or even with antibiotics combined with other components, such as vancomycin with PLGA [82,89], vancomycin with silica [83], levofloxacin with gold [87] and ciprofloxacin with PLLA/NaCl [91], showed to significantly reduce [82,83,86] or eliminate the bacterial load at the surgical site [81,85,87,89]. The non-association of the implants to these complements led to lower or absent antibacterial efficacy [81–83,85,86].

In what concerns the in vitro experiments, the strategies that effectively contributed to increasing the device antibacterial rate were adding ciprofloxacin with or without PLLA and NaCl [91], UMAO-phytic acid-Cu-3 or 5 [68], Se-CaP [80], 4% and 8% Ag nanoparticles [84], or hydroxyapatite with PSI10 [76] to the implant coating or composition.

3.3.2. Bioabsorption and Biodegradability

Several methods were implemented to evaluate the bioabsorption and biodegradability of the implants (Table 3), including gross pathology [71,83,87,89], bone histology, radiography [71,82,86,89], micro-CT [68,81,85–87] or sample weight after PBS immersion (in vitro) [76]. The follow-up period for in vivo studies ranged from 6 weeks [68] to 4 years [71], and the majority of the studies had a 12-week final time point [76,83–87,89]. The majority of the studies assumed a faster biodegradability rate as a desirable feature, while a few preferred an intermediate velocity [68,86] and others managed to find out ways to delay it [76,80,85].

The scaffolds containing a combination of poly-lactic acid derivatives with calcium phosphates or deproteinized bone particles showed different resorption rates in vivo, depending on the antibiotic incorporation within the implants, such as vancomycin [82,83,89], gentamicin and clindamycin [81], or none [71], as well as the integration of distinct com-
ponents in the composition of the scaffold, or the follow-up period of each experiment, between 8 and 13 weeks after implantation [81–83,89], with one study reporting results from a 2–4-year-long period [81]. Regarding biodegradation outcomes, they ranged from complete [81] to partial [82,83,89] or no degradation [71] along the established experimental periods. After 13 weeks, the PLGA scaffold containing PEG 400, β-tricalcium phosphate and carboxymethyl cellulose (CMC) carrying 4% gentamicin and 2.5% clindamycin [81] had been totally degraded, being the only implant made of a poly-lactic acid derivative reaching complete degradation by the end of the experiment, among the analyzed studies.

Among the implants that were partially degraded at the end of the experimental period, it is relevant to highlight the vancomycin-eluting PLGA nanofiber-loaded DPB (ANDB) scaffold, revealing scarce material remnants after 8 weeks [82]. This study also showed that the resorption of the scaffold with no vancomycin incorporation was delayed, if the antibiotic had been exclusively given intravenously, or prevented when no antibiotic was administered. Moreover, across a 12-week-long period, the vancomycin-loaded bone-like HA/poly (amino acid) (V-BHA/PA) scaffolds [89], with vancomycin-encapsulated PLGA microspheres, were all completely degraded, while the silica-coated Nanoha–gelatin/PLLA scaffolds with entrapped (SE-V) or absorbed (SA-V) vancomycin at 5%wt (SE-V5 or SA-V5) or 15%wt (SE-V15 or SA-V15) evidenced a more gradual degradation [83].

In the case study, in two patients with *Pseudomonas aeruginosa* tibial tunnel infection after 2 and 4 years of anterior cruciate ligament reconstruction, the 30% biphasic calcium phosphate and 70% PLDLA screws did not degrade in a 2-to-4-year period after surgery, with consequent transcutaneous extrusion of still intact bioabsorbable devices [71].

In a nutshell, among PU implants, the 10% Ag/n-HA/PU scaffold [86] and the K20 scaffold without vancomycin [85] had the fastest degradation rate, while the 1 or 5 mg Lev@ MSNs/n-HA/PU [87], the 0% Ag/n-HA/PU [86] and the K20/100 scaffolds had the slowest.

Finally, studies focusing on metallic implants used Mg or the Mg-Zn alloy within their core composition. Among the Mg nails, which were combined with UMAO-phytic acid, the implants with UMAO-phytic acid-Cu-3 showed lower degradation in 6 weeks, keeping the most complete morphology compared to Mg implants with UMAO-phytic acid-Cu-0 or UMAO-phytic acid (without Cu) [68], and a Mg-Zn alloy implant, namely, the AZ91 Mg alloy (Mg–9%Al–1%Zn) rod coated with HA, revealed a lower degradation rate than bare Mg alloy, in vitro, along 2 weeks [76].

### 3.3.3. Osteointegration

Such as for bioabsorption and biodegradability, the methods used to assess implant osteointegration were gross pathology [88,87,89], bone histology [87,71,76,80–87,89], radiography [82,86,87,89], micro-CT [68,76,80,81,83–87] and even MRI (Table 2) [71,76,83].

Taking into account the scaffolds that contained poly-lactic acid derivatives combined with calcium phosphates or deproteinized bone, two studies had a 12-week follow-up period [83,89], while all the other studies [81,82,91] had different ending time points, ranging from 40 days [91] to 4 years [71]. Different osseointegration rates and abilities were found among the implants, depending on their impregnation with antibiotics, gentamicin and clindamycin [81], vancomycin [82,83,89] or ciprofloxacin [91] and the different elements included within their composition, as well as the presence of infection by different bacteria (Table 3).

With the shortest follow-up period of 40 days, the ciprofloxacin biodegradable implantable matrices (CPX-IMs) made of PLLA and coated with PLLA or PLLA/sodium chloride (40% NaCl) showed different osseointegration rates according to their coating’s pore size, no pores (NPC), small pore size (SPC) (150–250 um) or large pore size (LPC) (250–350 um). The NPC CPX-IM did not undergo osteointegration, and the SPC CPX-IM and LPC CPX-IM had 30–40% or 60–70% of their surface area covered by osteoid formation, respectively [91]. Thus, the larger the pore size, the more efficient the osseointegration was. In 8 weeks, the ANDB scaffold underwent osseointegration, with a newly formed
trabecular structure and a bone callus largely repairing and bridging the bone defect. At this time point, the NDB scaffold, without incorporated vancomycin, although with intravenous prophylactic administration, had lower osteogenesis, while the NDB scaffold without vancomycin administration showed no osseointegration [82]. In 12 weeks, the V-BHA/PAA scaffold was almost completely replaced by bone, while the same scaffold without vancomycin did not osteointegrate [89]. In 13 weeks, the PLGA scaffolds containing PEG 400, β-tricalcium phosphate and carboxymethyl cellulose (CMC) carrying 4% gentamicin and 2.5% clindamycin evidenced osseointegration, presenting new bone ingrowth within the defect and areas of osteoid and calcified cartilage [81]. Finally, within 2–4 years, the 30% biphasic calcium phosphate and 70% PLDLA screws denoted closure of the previous tibia tunnel with newly grown bone [71].

Therefore, the implants that evidenced greater osseointegration efficacy were LPC CPX-IM in 40 days, the ANDB scaffold in 8 weeks, the 15%wt V-BHA/PAA scaffold and the 15%wt SE-V and SA-V scaffolds in 12 weeks, and the PLGA scaffolds containing PEG 400, β-tricalcium phosphate and carboxymethyl cellulose (CMC) carrying 4% gentamicin and 2.5% clindamycin in 13 weeks (Table 3).

Regarding implants incorporating a combination of polyurethane and calcium phosphates, the three studies that were conducted had a follow-up time of 12 weeks [85–87]. During that period, the n-HA/PU scaffolds showed different osseointegration properties. According to their Ag concentration (0%, 3% or 10%): the n-HA/PU scaffold without Ag (0%) showed a small amount of bone growing into the scaffold and bone destruction associated to the progression of the infection; the 3% Ag/n-HA/PU scaffold reported good bone healing, with large, heavy and mature new bone at the interface between the tibia and the materials, along with the voids and filling the bone marrow cavity; and the 10% Ag/n-HA/PU scaffold showed large and heavy new bone at the interface between the tibia and the scaffold, still having the presence of a dead cavity [86]. The K20/100 scaffold (loaded with vancomycin) preserved bone regenerative properties, fostering osseointegration with the bridging of the segmental bone defect, but no osseointegration was detected when no antibiotic was added to the scaffold [85]. Finally, the 1 and 5 mg Lev@ MSNs/n-HA/PU scaffolds showed gradual and slow new trabecular bone formation around the materials, with the newly formed trabecular bone surrounding and closely linked to the implants. However, the 5 mg Lev@ MSNs/n-HA/PU scaffold was associated with the highest new bone formation [87]. These findings suggest that the polyurethane and calcium phosphate scaffolds that provided a more efficient osseointegration within 12 weeks were the 3% Ag/n-HA/PU scaffold [86], the K20/100 scaffold [85] and the 5 mg Lev@ MSNs/n-HA/PU scaffold [87]. Two other implants were associated with efficient osseointegration: PCL discs coated with Se-CaP [80] and the 20% nHA@RGO scaffolds with 4% AgNP [84].

Finally, studies showcased implants made of metallic elements, with Mg [68] or Mg-Zn alloy [76] within their structure, and had distinct follow-up periods, namely, 4–6 weeks [68] or 4–12 weeks [76]. Within 6 weeks, the implants made of Mg UMAO-phytic acid (without Cu) or with Cu-0 or Cu-3 showed complete osseointegration, even though the scaffold without Cu led to a disorganized bone structure. Among the three, the scaffold with Cu-3 showed a faster osteointegration, within just 4 weeks [76]. Finally, the AZ91 Mg alloy rods coated with HA and PSI10 underwent osseointegration within 4 weeks, with good bone-promoting repair function; in 12 weeks, the lack of PSI10 led to just partial osseointegration [76].

3.4. Biodegradable vs. Non-Biodegradable: Comparative In Vitro and In Vivo Studies

3.4.1. Microbiology Analysis

Several bacteria were tested across comparative studies (Table 4), in which the performance of biodegradable implants was compared to standard materials such as titanium and Bio-Oss® (Bovine Porous bone mineral xenograft) [79]. MRSA strains were the most used bacteria to establish animal infection before the surgery [69,70,73–75,78,88]. Apart from
S. aureus, the studies also evaluated E. coli O157:H7 (NTCC 12900) [77] and Acinetobacter baumannii (Ab307-0294) [73].
Table 4. Analyses of implants’ biodegradability, osteointegration and antibacterial properties across comparative studies.

| Ref. # | Implant Type (Scaffold, Screw, . . .) | Study Design/Type of Study | Surgical Site | Previous Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antimicrobial Admin. | Sacrifice Time-Point/ Follow-Up Time After Surgery | Infection | Bioabsorption/ Biodegradability | Osteointegration | Main Outcome |
|--------|-------------------------------------|---------------------------|---------------|-------------------|--------------------------------------|---------------------------------|------------------------------------------------|-----------|-----------------------------|----------------|-------------|
|        |                                     |                           |               |                   |                                      |                                 | 15 days                                       |           | 60 days                     |                | P3HB/HA and P3HB led to quicker suppression of infection and recovery of the support ability of the affected limb than Bio-Oss®. However, P3HB/HA composite implants showed inferior biomechanical properties than P3HB since cortical bone had large lacunae and was rather loosely structured. P3HB-based materials showed pronounced osteoplastic properties and slow degradation in vivo, enabling normal reparative osteogenesis. |
|        |                                     |                           |               |                   |                                      |                                 | 30 days S. aureus (44.1%) and associations of Gram-positive and Gram-negative anaerobic microorganisms and E. coli (55.9%) |           | -                          | Partially | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 60 days                                       |           | Yes                         | -              | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 90 days No bacteria                        |           | -                          | Yes            | Yes                      |
|        |                                     |                           |               |                   |                                      |                                 | 120 days                                      |           | -                          | Yes            | Yes                      |
|        |                                     |                           |               |                   |                                      |                                 | 15 days                                       |           | -                          | Yes            | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 30 days No bacteria                        |           | Partially (lower rate) | Partially | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 60 days                                       |           | -                          | Yes            | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 90 days No bacteria                        |           | Mostly                     | Yes            | Yes          |
|        |                                     |                           |               |                   |                                      |                                 | 120 days                                      |           | -                          | Yes            | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 15 days                                       |           | -                          | Yes            | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 30 days S. aureus (48.2%) and associations of Gram-positive and Gram-negative anaerobic microorganisms and E. coli |           | -                          | -              | -                          |
|        |                                     |                           |               |                   |                                      |                                 | 60 days                                       |           | -                          | -              | -                          |

P3HB/HA pellets + Tienam

Bio-Oss® (control)
| Ref. # | Implant Type (Scaffold, Screw, . . .) | Surgical Site | Microorg. | Previous Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antimicrobial Admin. | Sacrifice Time-Point/Follow-Up Time After Surgery | Infection | Bioabsorption/Biodegradability | Osteointegration | Main Outcome |
|--------|----------------------------------|--------------|-----------|-------------------|--------------------------------------|---------------------------------|--------------------------------|------------|-----------------------------|----------------|--------------|
|        |                                  |              |           |                   |                                      |                                 |                                |            |                             |                |              |
|        |                                  |              |           |                   |                                      |                                 |                                |            |                             |                |              |
| [73]   | AZ91 rod                         | In vivo      | Humeral head | A. baumannii (AKM07-0294) | Yes | Just before implantation | No | 7 days | No antimicrobial effect | - | - | - | Partially * | - | - | AZ91 did not produce antimicrobial effects. |
|        | c.p. Ti rod (control)            |              |            |                   |                                      |                                 |                                |            |                             |                |              |
|        | Mg-0.1Ga-0.1Sr rod               | In vivo      | Femur medullary cavity | S. aureus (ATCC 43300) | Yes | Just before implantation | No | 5 days | Few bacterial colonies | - | - | - | Yes (lower)** | Yes | - | Mg alloys outperformed c.p. Ti in inhibiting S. aureus on the rods surface. Such antibacterial activity was improved through addition of micro-content of Ga and Sr (0.1 wt%). |
| [74]   | Pure Mg rod                      |              |            |                   |                                      |                                 |                                |            |                             |                |              |
|        | Mg-0.1Sr rod                     |              |            |                   |                                      |                                 |                                |            |                             |                |              |
|        | Mg-0.1Ga rod                     | In vivo      | Femur medullary cavity | S. aureus (ATCC 43300) | Yes | Just before implantation | No | 5 days | Some bacterial colonies | - | - | - | Yes (higher)** | Yes | - | Mg alloys outperformed c.p. Ti in inhibiting S. aureus on the rods surface. Such antibacterial activity was improved through addition of micro-content of Ga and Sr (0.1 wt%). |
|        | c.p. Ti rod (negative control)   |              |            |                   |                                      |                                 |                                |            |                             |                |              |
|        | c.p. Ti rod (negative control)   |              |            |                   |                                      |                                 |                                |            |                             |                |              |
|        | None (positive control)          |              |            |                   |                                      |                                 |                                |            |                             |                |              |

S. aureus (48.2%) and associations of Gram-positive and Gram-negative anaerobic microorganisms and E. coli.

AZ91 did not produce antimicrobial effects.

None (positive control) | S. aureus (ATCC 43300) | Yes | Just before implantation | | - | - | - | - | - | - | - |
| Ref. # | Implant Type (Scaffold, Screw, ...) | Study Design/Type of Study | Surgical Site | Previous Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antibacterial Admin. | Sacrifice Time Point/Follow-Up Time After Surgery | Infection | Bioabsorption/ Biodegradability | Osteointegration | Main Outcome |
|--------|-----------------------------------|----------------------------|--------------|-------------------|---------------------------------------|----------------------------------|-----------------------------------------------|-----------|-----------------------------|----------------|---------------|
| [72]   | Mg screw                          | Retrospective cohort study | Tibia medial malleolus | No                | -                                     | -                                | Mean time of 24.6 ± 10.5 months (12–53 months) | -         | -                           | -              | Bioabsorbable Mg and titanium screws had similar therapeutic efficacy in MM fracture fixation. There was no implant removal with Mg screws. |
|        | Ti screw                          |                            |              |                   |                                       | -                                | No deep infection                  | -         | -                           | -              |               |
| [75]   | Zn-2Cu cylindric rod              | In vivo                    | Femur medullary cavity | Yes | Soaked in implants | No | 3 and 6 weeks | Significantly lesser bacteria were found | Few bacteria | Milder signs | - | The Zn-2Cu alloy exerted effective bacterial-killing capability and inhibited the inflammatory and toxic side-effects induced by MRSA bacteria in the rat femur. |
| Ti cylindric rod |                            |              |              |                   |                                       | -                                | No deep infection                  | -         | -                           | -              |               |
|        | None                              |                            |              |                   |                                       | -                                | No                             | -         | -                           | -              |               |
| [69]   | Mg0.25Cu intramedullary nail      | In vivo                    | Tibial metaphysis | Yes | Prior to surgery (4 weeks) | No | 4 weeks | Small number of bacteria | - | No | - | - | The Mg0.25Cu alloy demonstrated antibacterial properties and a therapeutic effect in chronic tibial osteomyelitis. |
| Ti intramedullary nail |                            |              |              |                   |                                       | -                                | -                             | -         | -                           | -              |               |
| [68]   | Mg-Nd-Zn-Zr (JDBM BioMg alloy) cylinder | In vivo | Distal femur | MRSA | Yes | - | 4 weeks | Large number of bacterial colonies | - | Yes | - | - | The JDBM BioMg alloy implant showed antibacterial properties against MRSA, decreasing biofilm formation. |
| Ti cylinder |                                |              |              |                   |                                       | -                                | -                             | -         | -                           | -              |               |

**Table 4. Cont.**
| Ref. # | Implant Type (Scaffold, Screw, . . .) | Study Design/Type of Study | Surgical Site | Previous Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antimicrobial Admin. | Sacrifice Time/Point Follow-Up Time After Surgery | Infection | Bioabsorption/Biodegradability | Osteointegration | Main Outcome |
|--------|----------------------------------|---------------------------|---------------|-------------------|------------------------------------|---------------------------------|-------------------------------|-----------|-----------------------------|----------------|-------------|
| [78]   | Mg-Zn alloy Kirschner wires      | In vivo                   | Distal Femur  | Yes               | MRSA (ATCC 43300)                 | Just before implantation       | -                             | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 2 weeks                       | Presence of MRSA | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 4 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 6 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 8 weeks                       | Presence of MRSA | No bacteria      | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 2 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 4 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 6 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 8 weeks                       | Presence of MRSA | No bacteria      | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 2 weeks                       | -         | -                           | -              | No          |
|        |                                  |                           |               |                   |                                    |                                 | 4 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 6 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 8 weeks                       | Presence of MRSA | No bacteria      | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 2 weeks                       | -         | -                           | -              | No          |
|        |                                  |                           |               |                   |                                    |                                 | 4 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 6 weeks                       | -         | -                           | -              | -           |
|        |                                  |                           |               |                   |                                    |                                 | 8 weeks                       | Presence of MRSA | No bacteria      | -              | -           |

Better bone-implant integration was observed around the Mg-Zn alloy implants compared with Ti in the absence of MRSA. The corrosion product layer deposited on the surface of the Mg-Zn alloy implant retarded the corrosion of the implant, promoting osteointegration.
Table 4. Cont.

| Ref. # | Implant Type (Scaffold, Screw, …) | Study Design/Type of Study | Surgical Site | Microorg. | Previous Infection | Inoculation/Seeding of Microorganisms | Prophylactic Antiinfectious Admin. | Sacrifice Time Point/ Follow-Up Time After Surgery | Infection | Bioabsorption/ Biodegradability | Osteointegration | Main Outcome |
|--------|----------------------------------|---------------------------|---------------|-----------|-------------------|--------------------------------------|----------------------------------|------------------------------------------|-----------|-----------------|-----------------|-------------|
|        | Zn–2Ag cylindric intramedullary nail | In vivo                   | Femoral condyles | MRSA      | Yes               | Soaked in implants                   | "                      | 3 and 6 weeks                          | Very few bacteria in the surrounding bone tissue; no bacteria on the nail surface | Almost completely suppressed | Milder signs | -    | -              | Zn–2Ag alloy prevented MRSA infection and no osteomyelitis formation was observed, while promoting osseointegration. |
| [70]   | c.p. Ti cylindric intramedullary nail | In vivo                   | Femoral condyles | MRSA      | Yes               | Soaked in implants                   | "                      | 3 and 6 weeks                          | Large number of bacteria on the nail surface and surrounding bone tissue | Yes               | Yes           | -    | -              |
|        | Zn–2Ag screw                    |                           | Femoral condyle split-fracture | -         | No                | "                                   | 3 months                       | -                                        | -                      | Yes               | Yes          | -    | -              |
|        | Ti–6Al–4V screw                  |                           | Femoral condyle split-fracture | -         | No                | No                                   | 3 months                       | -                                        | -                      | Yes               | Yes          | -    | -              |
|        | Mg–1Zn–0.5Sn rod                 | In vivo                   | S. aureus (ATCC 25923) [#] | No        | No, Yes [#]      | Penicillin postop, No [#]            | 1.7 and 14 days            | Lowest number of bacterial colonies/smaller colonies [#] | -                      | -                  | Slower degradation rate *** [#] | Mg–1Zn–0.5Sn materials exhibited significant antibacterial ability compared to Ti materials. Mg–1Zn–0.5Sn had its degradation rate significantly reduced. |
| [77]   | Mg–1Zn rod                      | In vivo                   | Femoral condyle | S. aureus (ATCC 25923) [#] | E.coli O157 (H7 NTCC 12500) [#] | No, Yes [#] | 1.7 and 14 days | Low number of bacterial colonies/smaller colonies [#] | -                      | -                  | -             | -                  |
|        | Ti rod [#]                      |                           |                |            |                   |                                       |                                | Higher number of bacterial colonies [#] | -                      | -                  | -             | -                  |

Notes: * These results report to visual examination after implant removal. ** After removal, the implant underwent SEM observation. *** Results obtained after emersion test. [#] Experiment results in vitro. [##] Chlorhexidine was used as an antiseptic solution to wash out the bone cavity before the implantation of bone substitutes.
The microbiology methods to assess infection were implant culture, determination of colony-forming units (CFU) and biofilm formation in vitro and in vivo. One study compared P3HB pellets with or without Tienam, using Bio-Oss® as a control. The P3HB pellets without Tienam reported the presence of S. aureus (44.1%) and associations of Gram-positive and Gram-negative anaerobic microorganisms and E. coli (55.9%) 30 days after implantation, even though a new evaluation at day 90 showed no bacteria [79]. P3HB pellets with Tienam were associated with no bacteria at these two microbial analysis timepoints, while Bio-Oss® was not able to eliminate the presence of S. aureus (48.2%) and associations of Gram-positive and Gram-negative anaerobic microorganisms and E. coli at both timepoints [79]. The remaining studies compared metallic implants with titanium implants (controls).

One retrospective cohort study compared patients with median malleolar fractures fixed with bioabsorbable Mg screws (23 patients) and with conventional titanium screws. In both, no evidence of deep infection in a period of 12 to 53 months after implantation was observed [72].

Four studies used Mg-Zn alloys to manufacture their implants [73,77,78,88], and some added to this alloy other metallic elements, including Al (AZ91) [73], Nd and Zr (JDBM BioMg alloy) [88], and 0.5Sn [77]. In two of these studies [73,78], the alloy and the Ti controls had similar effects on bacteria elimination, since they were not able to suppress infection, reporting the presence of A. baumannii (Ab307-0294) [73] or MRSA (ATCC 43300) [78] 7 days and 8 weeks, respectively, after implantation. Moreover, in one study, the control group, in which no bacteria were inoculated, reported no infection [78]. In another study, the JDBM BioMg alloy cylinder was associated with a small number of bacteria 4 weeks after implantation, compared to large amounts of bacteria present in the Ti control group at the same timepoint [88]. Moreover, in one study, three types of implants—a Mg-1Zn-0.5Sn rod, a Mg-1Zn rod and a Ti rod—were tested and compared regarding their antibacterial properties in vitro. The Mg-1Zn rod led to a low number of bacterial colonies. However, adding 0.5Sn to this Mg-1Zn alloy reduced even further the number of bacterial colonies among these three implants.

Other studies alloyed other different metallic elements with Mg. One study manufactured a Mg-0.1Ga-0.1Sr rod and compared it with simpler forms of the alloy, such as Mg-0.1Sr rod, Mg-0.1Ga rod and pure Mg [74]. The microbiology analysis was conducted 5 days after implantation. At this time point, the Mg-0.1Ga-0.1Sr rod was associated with fewer bacterial colonies, the Mg-0.1Sr and Mg-0.1Ga rods got some bacterial colonies, the pure Mg rod led to many bacterial colonies, and the Ti rod showed the highest number of bacterial colonies. Regarding the implant with Mg and 0.25Cu in an intramedullary nail, almost no bacteria have grown, 4 weeks after implantation, while Ti had multiple colonies, also confirmed through imagological findings [69].

Finally, two studies alloyed Zn with 2Cu [75] and 2Ag [70]. These alloys reported significantly lesser bacteria than Ti [75] and very few bacteria in the surrounding bone tissue and an absence of bacteria on the nail surface [70]. Two studies reported milder signs of infection; however, in the Ti implant controls, the nail surface and the bone tissues surrounding the nails contained multiple MRSA colonies within a biofilm matrix [70,75].

3.4.2. Bioabsorption and Biodegradability

There was some variability in bioabsorption and biodegradability properties among the studied materials. Those properties were assessed in in vivo studies through histological analyses [70,75,79], visual examination [73], scanning electron microscopy (SEM) [74], X-ray [78] and MRI [69]. Some articles assessed their implant degradation ability in vitro, through implant incubation in simulated body fluid (SBF) [88], in Trypticase Soy Broth containing MRSA [78] or PBS [77]. The implant’s resorption follow-up time ranged from 5 days [74] to 53 months [72].
Among the comparative studies, most of the articles showcased metallic implants, whilst only one developed a polymer and hydroxyapatite composite-based implant [79]. This article developed P3HB pellets, loaded or not with HA. Both variants showed a slow degradation rate, even though the P3HB/HA composite implant had an even slower resorption rate [79]. Ninety days after surgery, the P3HB pellets were fully degraded, while the P3HB/HA pellets still had little remnants [79].

Regarding metallic implants, Mg was the most employed element. It was studied either alone or alloyed with other metals, usually aiming to delay its intrinsic degradation rate. One of the two studies that used bare Mg screws reported full degradation when analyzed across a 12–53-month period after surgery, preventing posterior implant removal procedures (0%) when compared to Ti implants (20%) [72]. Moreover, in another study, in 5 days post-op, pure Mg rods exhibited a high corrosion rate, which could be delayed when alloyed with 0.1Sr or a Mg-0.1Ga-0.1Sr [74].

The other studies in which Mg played a crucial role either alloyed it with Cu, in a Mg0.25Cu intramedullary nail partially degraded 4 weeks after implantation [69] or, in the majority of the cases, with Zn. The Mg-Zn alloy was employed in four studies, reporting a relatively slow absorption rate. Mg-Zn alloy Kirschner wires showed good corrosion resistance 2 weeks after implantation [78]. Moreover, 7 days after surgery, an AZ91 rod (with Al) showed a slower degradation than Mg, although evidencing corrosion products on its surface [73]. Moreover, in vitro analyses over 7 days revealed that a Mg-1.5Zn-0.5Sn rod had a slow degradation rate, since the SnO2 forming all over the implant surface helped prevent pitting corrosion [77], and Mg-Nd-Zn-Zr (JDBM BioMg alloy) cylinder [88] degradation decreased with the immersion time.

Regarding other Zn alloys, a Zn–2Ag screw used to fix a femoral condylar split-fracture showed many degradation products 3 months after surgery [70], and Zn-2Cu alloy cylindrical rods also evidenced degradation products 3–6 weeks after surgery [75].

3.4.3. Osteointegration

Different material-based implants showed different osseointegration properties (Table 4). Every research in which those properties were assessed performed histological analyses [69, 70, 73–75, 78, 79, 88]. Other complementary methods included X-ray [69, 70, 78, 79, 88], gross observation [69], MRI [69] and micro-CT [70, 78]. Additionally, the observation period ranged from 4 weeks [69, 88] to 120 days [79].

Most of the studies presented metallic implants, while only one came out with a composite-based implant, resulting from the combination of a polymer with HA [79]. In this study, both P3HB and P3HB/HA implants loaded with Tienam showed a more complete repair of the respective model bone defect than the commercial material Bio-Oss® , contributing to the support ability and functional recovery of the affected limbs [79]. Interestingly, the P3HB implants showed better biomechanical properties than P3HB/HA implants 60 days after surgery, whose developing cortical bone evidenced larger lacunae and was loosely structured; however, 90 days after surgery, the cortical bone had almost been completely formed [79].

When comparing osteointegration properties of Mg-Zn and Ti implants, Mg-Zn implants were better succeeded. One study referred to a greater bone-to-implant contact with the Mg-Zn Kirschner wires, in 8 weeks, since the corrosion layer formed on top of these implants leads to the development of a more favorable microenvironment for osseointegration and bone-implant integration than Ti [78]. Moreover, 4 weeks after implantation, Mg-Nd-Zn-Zr (JDBM BioMg alloy) implants revealed a higher volume of mineralized bone, higher trabecular number and lower trabecular spacing in the previously established defect than Ti implants [88].

Other Mg alloyed implants were also assessed showing promising results. Four weeks after implantation, Mg0.25Cu intramedullary nails led to bone defect repair through the regeneration of thin new trabecular bone, while Ti implants led to bone tissue destruction [69]. On the other hand, pure Mg, Mg-0.1Sr, Mg-0.1Ga, and Mg-0.1Ga-0.1Sr implants
had a large number of newly formed fibrous tissue in their vicinity, 5 days after surgery, even though longer experiments are required to assess the Sr and Ga species role on bone tissue formation [74]. Additionally, Zn alloys also demonstrated interesting results towards osseointegration. Thus, 3–6 weeks after implantation, Zn–2Cu rods were associated with more mature new bone formation and higher bone mass, with less bone being resorbed, while Ti implants led to more immature new bone and more osteoclastic bone resorption [75]. Finally, both Zn–2Ag and Ti–6Al–4V screws showed great efficacy in fracture repair, within 3 months [70]. The Zn–2Ag screw inhibited osteoclast differentiation, promoting osseointegration with new bone tissue forming around the screws.

3.5. Risk of Bias Analysis

The twenty-three selected studies included 1 retrospective cohort study, 1 case series and 21 animal model studies, mainly in sheep (1), rat (9) and rabbit (11). None of these studies were excluded based on quality. The results of the risk of bias assessment included in the study are presented in the Supplementary Material section (Supplementary Material Table S2). Most of the studies showed low risk of bias practices and results. One study did not report whether caregivers and researchers were blinded [87]. Seven studies did not report randomization of the administration dose or exposure level [70,73,80,85–88]. One study did not report if allocations to study groups were adequately concealed [80].

4. Discussion

The repair of bone fractures usually requires internal fixation of bone fragments, with numerous sorts of devices, such as wires, pins, screws, plates, intramedullary nails or rods being commonly used to stabilize the fracture and restore early mobility, limb function or weight-bearing ability [92]. Nowadays, nondegradable metallic implants made of stainless steel or titanium alloys are usually the first-line choice for bone internal stabilization. However, the wear associated with long-term exposure to these materials can lead to some health complications, such as foreign body reaction or inflammation induced by the release of certain ions or particles [93], eventually resulting in a second surgery for implant removal, with a higher risk of infection and healthcare-associated costs [94]. Additionally, implant-associated infections can also elicit revision surgeries and debridement. To overcome these drawbacks, and thanks to innovation in the biomedical field, various biodegradable devices have been developed, some of them assuming intrinsic antibacterial properties, providing physical support for tissues, fostering tissue repair, regeneration or facilitating local drug delivery [95], including antibiotics. Biodegradable orthopedic implants are expected to gradually degrade at a pace compatible with the bone healing process while being slowly removed by the body [94].

A systematic review of the most recently published evidence over the last 5 years was conducted to evaluate whether biodegradable orthopedic implants could reduce the prevalence of implant-associated infections, while undergoing osteointegration, contributing to increasing the strength and biomechanical support in previously established bone defects and avoiding the need for second revision surgeries. To be included in this systematic review, the studies had to evaluate at least one of the following features in vivo: antibacterial activity, biodegradability or osteointegration, a requisite found across 23 studies.

The bacterial adhesion and biofilm formation around the implant’s surface is a leading cause of implant failure [96]. Since human pathogens’ resistance to antibiotics has been continuously increasing [86], the development of alternative ways to outrun the establishment of infection is required. Thus, the development of coatings with antibacterial activity conferred through some components other than antibiotics comes out as an attractive solution. Those components can be antimicrobial peptides, inorganic antibacterial metal elements or antibacterial polymers [96]. Coatings can be applied through some techniques, including electrodeposition [97], electrophoretic deposition [98], dip-coating [99], thermal spraying [100], chemical conversion or a biomimetic approach [101,102].
Besides infection prevention, coatings can also delay implant degradation and corrosion rate [68] and improve the osteoinductive and osteoconductive properties of the implant’s surface, strengthening the adhesion between the implant and the peri-implant newly formed bone [103]. Herein, we highlight some of the coatings explored in the reviewed studies we presume to be great alternatives to the use of antibiotics. Jiaqi et al., 2019, developed a coating of ultrasonic micro-arc oxidation phytic acid copper (UMAO-phytic acid-Cu) upon Mg implants. This coating was found to reduce bacterial propagation while decreasing the implant corrosion rate and promoting bone growth, in vivo [68]. Researchers also concluded that the higher the content of Cu2+ present in the coating film per unit time, the stronger its antibacterial properties, but also the stronger its cytotoxicity, inhibiting cell proliferation and osteoblast differentiation [68]. Hence, the copper-loaded time of 3 min was preferred to 1 or 5 min. The mechanism underlying copper antibacterial activity has to do with the interaction between positive copper ions and the negative charges on the bacterial cell surface, causing the copper ions to detach from the coating surface towards the bacterial cell membrane, and then through its body, destroying it [68]. Moreover, Jin-huan et al., 2014, investigated the AZ91 magnesium alloy coated with hydroxyapatite and an antimicrobial peptide, named PSI 10 [76]. Antimicrobial peptides are produced by all living species and belong to innate immunity, taking part in the primary host response against microorganisms [104], inducing lower antimicrobial resistance than conventional antibiotics [76]. This coating was able to sustain its antimicrobial effect throughout the experiment (7 days), as antimicrobial peptides incorporated onto HA crystals were slowly released, while evidencing a bacterial inhibition rate of over 50% after 4 days, in vitro [76]. In vivo, it promoted greater osteoblastic activity than pure and HA-coated magnesium alloys [76]. Since antimicrobial peptides have cationic properties, they selectively interact with bacteria cells, which are more negatively charged than mammalian cells [105]. Hence, antimicrobial peptides are biocompatible with osteoblasts, while evidencing substantial antibacterial activity against both Gram-positive and negative bacteria [106].

Finally, Cedryck et al., 2020, developed a two-layered, “bifunctional” coating on a 3D-printed (PCL) scaffold: the top layer, made of CaP, aiming to stimulate osteoblast cell functions, and the bottom layer, containing Selenium (Se) nanoparticles, aiming to release this antimicrobial agent [80]. This coating was able to inhibit S. aureus biofilm formation through the release of HSe ions [80]. Considering that only 15% of the ions were released after 3 weeks, it is expected that this coating will have a prolonged and sustained antibacterial performance [80]. Furthermore, Se has shown good osteogenic properties, increasing the expression of osteogenesis genes such as alkaline phosphatase, osteocalcin or collagen-I, promoting osteoblast differentiation or metabolism; this may explain why the Se-CaP coating was able to support higher bone formation than the CaP-only coating [80]. Interestingly, compared to silver nanoparticles, Se has much lower cell toxicity [107].

Even though the antibacterial activity of these coatings had only been evaluated in vitro, their favorable results in this field allied to good cell biocompatibility make them promising candidates to replace the use of antibiotics for preventing implant-associated infections. Another way found to curb infection without antibiotics was through the incorporation of silver nanoparticles within the implants’ core. Dongli et al., 2018, developed a composite scaffold whose core constitution contained silver phosphate particles [86], similar to Weizong et al., 2020, who included silver nanoparticles in their scaffold, also flanked by reduced graphene oxide (RGO) and n-Ha [84]. Silver ions released from hydroxyapatite create a bacteriostatic environment around the implant [108]. Their antibacterial performance resides in the ability to induce the degradation of the bacterial cell membrane, the ribosomes denaturation and preclude the bacterial DNA replication [109]. This bactericidal effect is achieved at low concentrations, as 35 parts per million (ppm), with no cytotoxicity for mammalian cells [110]. Both studies reported favorable results, in vivo. Within 12 weeks, the implants studied by Dongli et al., 2018, led to no significant bone infection symptoms [86] and the implant of Weizong et al., 2020, effectively eliminated the infection and inhibited biofilm formation [84].
Across the reviewed comparative studies, several metallic alloys containing either Mg or Zn or both were implanted in the context of infection, and their performance was compared to pure titanium, the most used material for permanent implants contacting with bone [96]. Mg alloys express a high chemical and electrochemical activity, therefore being prone to degradation in physiological environments [74]. The corrosion of Mg and consequent release of Mg$^{2+}$ ions generate a rapid increase in pH in the peri-implant surrounding tissues, inducing toxic effects on bacteria. High alkalinity inhibits bacteria adhesion ability by decreasing their surface hydrophobicity [111], and disrupts the proton electrochemical gradient in the intermembrane space of bacteria, reducing the synthesis of ATP by excessive consumption of protons [112]. However, the fast degradation rate of Mg does not usually match the bone healing process, so it is suggested to alloy Mg with other metals to solve this impairment, increasing corrosion resistance and biomechanical properties, for an adequate fracture internal fixation [88]. On the other hand, Zn ions hold osteogenic properties, stimulating osteoblasts by promoting cell replication, alkaline phosphatase activity, synthesis of collagen and osteoblast marker gene expression [113–115]. Apart from the magnesium alloy AZ91 (Mg–9%Al–1%Zn) [73], which showed no antibacterial activity in vivo, in 7 days, the remaining studies evidenced a satisfactory antibacterial efficacy. The magnesium alloy AZ91’s slow corrosion rate hindered the production of a significant alkaline shift in pH in vivo, suppressing the implant’s antibacterial properties [73]. However, other studies, which included the Mg-Zn alloy within their implant’s composition, came to different conclusions: an Mg-Zn alloy implant [78] evidenced a significantly lower bacterial burden than Ti implants, although it did not eliminate these bacteria within 8 weeks, while an Mg-Nd-Zn-Zr implant (JDBM BioMg alloy) [88] showed no signs of infection within 4 weeks. One of the reasons to explain the apparent success of the JDBM BioMg alloy implant in inhibiting infection has to do with the high release of Mg$^{2+}$ ions during the early implantation stage. Mg$^{2+}$ activates macrophages in the pro-inflammatory M1 phenotype, which release pro-inflammatory cytokines and take part in the immune response against microorganisms, rather than the anti-inflammatory M2 phenotype, enhancing the phagocytic capacity [88].

Other alloys of Mg–Mg-0.1Ga-0.1Sr [74] and Mg0.25Cu [69] revealed high efficacy in tackling bacteria. The Mg-0.1Ga-0.1Sr implants [74] showed a slower degradation rate than pure Mg implants, with higher antibacterial activity and suppressing bacterial existence within 5 days [74]. Given that the Mg-0.1Ga-0.1Sr implant induced a lower pH increase and detained higher bactericide activity than pure Mg implants, Zhihan et al., 2019, concluded that the key factor for antibacterial performance was the release of Sr$^{2+}$ and Ga$^{3+}$ ions, rather than Mg$^{2+}$ ions or pH increase [74]. Sr$^{2+}$ ions can also play a role in bone cell growth, although a longer implantation period would be required to assess the mechanisms behind Ga and Sr species on osteogenesis [74]. On the other hand, the Mg 0.25 Cu implant was responsible for the suppression of bone infection within 9 weeks [69]. Besides antibacterial properties, Copper integrates many metalloenzymes with important functions in the human body and stimulates osteogenesis and angiogenesis, crucial for repairing bone defects as a result of infection [116]. The Mg0.25 Cu alloy presented an excellent antibacterial activity, hindering bacterial adhesion and biofilm formation, as well as bacterial virulence and MRSA genetic drug resistance [69].

To overcome some Mg drawbacks, such as fast corrosion rate, low mechanical strength, accumulation of released protons or pH elevation, some authors turned to Zn-based materials as an appealing alternative for orthopedic implants, attracted by their great mechanical properties, degradation dynamics and osteogenic ability [75]. Among the Zn alloys developed across the reviewed studies, Zn2Ag [70] and Zn2Cu [75] were linked to great antibacterial activity and milder signs of infection, due to their ability to prevent bacterial adhesion and biofilm formation. Zn alone also exerts some inhibitory effects on bacteria [75]. While the Zn-2Ag alloy was reported to down-regulate bacterial genes involved in adhesion, colonization, the biofilm-thickening phase, virulence and drug resistance [70], the Zn-2Cu alloy also offered protection against MRSA inflammatory and
toxic effects [75]. Moreover, the addition of Cu to the Zn-2Cu alloy helped increase its strength while maintaining Zn ductility [75]. This alloy was associated with improved osteogenesis and cytocompatibility, with higher mature new bone and bone mass around the implant interface and little osteoclastogenesis [75]. On the other hand, although the Zn-2Ag alloy did not directly elicit osteogenic differentiation, its good biodegradability and ability to restrain inflammatory response caused by degradation products were responsible for actively promoting peri-implant osseointegration, besides inhibiting osteoclastic activity [70]. This alloy also exhibited excellent mechanical properties [70]. The Zn-2Ag alloy evidenced some advantages over other materials. For instance, organic polymers such as PGA, PLA, and PLLA/PDLLA produce acidic environments because of their degradation products, and Mg-based implants elicit an alkaline environment in the implantation site surroundings, leading to abnormal inflammatory responses [117,118]. Additionally, the Zn–2Ag alloy developed by Xinhua et al., 2021, evidenced significant superiority over other Zn-based alloys due to its ability to suppress infection and osteoclastogenesis and enhance osteointegration, mainly in low-immunity patients with a considerable prevalence of bone-related infections [70].

Some of the reasons for choosing metallic implants instead of implants made of polymers or hydroxyapatite have to do with the confidence metals provide in terms of resistance, load-bearing capacity and bone function restoration after trauma. However, some non-metallic implants developed across the reviewed studies revealed a great ability to fix unstable bone, with good osteogenic properties. The core material of these implants usually does not have intrinsic antibacterial properties, unless some antibiotics, metallic particles with anti-bacterial properties or other compounds with the same goal are incorporated within the implant.

Regarding implant manufacture, production processes used in the studies under focus spread over a myriad of different manufacturing approaches. The metal implants were mostly prepared using powder metallurgy, where the alloying is easier to process and fine tune. Concerning thermoplastics, the materials are also, tentatively, processed in powder forms, and consolidated using either solvents or hot forming. Depending on the applications, there is dominance on the application/shapes that are commonly processed for thermoplastics—scaffolds and discs. The dominant implant types for metal-based processes are mostly slim cylindrical geometries such as nails, rods and cylinders.

An analysis of the scoped results showcases that 3D printing (not additive manufacturing) is used at least in one of the production stages, either at defining the mold shape, or at producing the final part itself. Concerning metal-based implants, 3D printing is not yet a significantly used method. The design stage is still not sufficiently exploited, and thus the added value is not driving the printing process. In the case where selective laser melting was used [88], the cylinder walls were functionalized to take advantage of the intrinsically complex design possibilities. In May et al.’s work, the metal-based screw is 3D printed and post-processed with cold-rolling to attribute further mechanical properties [72]. This combination tackles a multi-objective purpose, where the enhanced mechanical properties driven by the cold rolling are exacerbated by the geometries/ shapes of the screw walls. There is currently no other process that allows such complex designs, with such ease of manufacturing.

Three-dimensional printing and additive manufacturing in general will allow for, in the future, as inception showcased in this analysis, a combination of process performance with material performance as well as the design possibilities. These combinations will allow for Venn-like analysis where different combinations of materials, together with specific processes, will unlock new designs and thus new application domains.

All the metallic and non-metallic implants can be precursors and reflect the incessant search for the perfect orthopedic implant for internal bone fixation or bone regeneration. This hypothetic implant shall fulfill some features, including (1) a biodegradation rate consistent with the pace of new bone formation and native tissue regeneration [86], (2) intrinsic antibacterial and anti-biofilm properties, (3) biocompatibility and biosafety, precluding
a strong inflammatory response and releasing degradation products well tolerated by
the host [119], (4) fostering osteointegration and osteogenic properties, including with
incorporation of osteogenic factors or precursors [120], (5) osteoconductive properties, with
interconnected pores with adequate size, to allow for cell migration throughout the struc-
ture, as well as transport of waste products (in the case of a scaffold) [120], (6) fixation to
the surrounding tissues, allowing for stability and load transfer [121], (7) surface roughness
on a nanometer scale to promote cell adherence [121], (8) mechanical properties similar
to the bone, including strength and weight-bearing ability, and (9) filling the bone void,
mimicking the true native tissue morphology to guide the regeneration accordingly (in the
case of a scaffold) [120].

The present work faced some limitations. On the one hand, most of the reviewed stud-
ies did not state a clear distinction between the concepts of biodegradable and bioabsorbable
implants, so these terms were considered to have the same meaning in our analyses. On
the other hand, the majority of studies did not have a follow-up period long enough for the
natural development of infection, so the microorganisms were artificially seeded into the
surgical site and therefore the infection was pre-established before surgery. There was only
one study [72] in which no bacteria were inoculated, with 48 patients being followed for a
12–53-month period of time, implanted with either Mg or Ti implants, even in this case, and
despite the kind of implant, no signs of infection were detected during that period, although
Ti implants underwent a higher removal rate due to pain or difficulty in shoe-wearing.
Additionally, the different studies employed different methods to evaluate implant efficacy
regarding biodegradability, osteointegration and antibacterial activity: some studies did
not address all these variables and others evaluated some features only in vitro rather than
in vivo. Moreover, some relevant aspects of the implantation success, such as the biosafety
of implants and the impact of their degradation products on the organism as a whole or in
specific organs, were not exhaustively addressed in this work. Finally, the existence of a
timeframe in the inclusion criteria and the fact that no metanalyses were carried out also
stand out as two additional limitations.

5. Conclusions

Implant-associated infections are among the leading causes of failure of orthopedic
implants, usually leading to a second revision surgery with additional costs for healthcare
systems and discomfort for patients. The present systematic review made an overview
of the most recent literature about biodegradable orthopedic implants, with the ability to
be gradually absorbed within the organism, provide mechanical and structural support
for the unstable bone lesion and foster the elongation of new bone while hindering the
development of bacterial biofilms. Among metallic implants, the Mg- and Zn-based alloys
were the most attractive materials, usually combined with other metallic elements such
as Ag or Cu, among others, with intrinsic antibacterial activity. Other biopolymers and
hydroxyapatite-based implants were also assessed, usually associated with innovative coat-
ings or other components within the implant core structure with antibacterial properties.
These implants are expected to be a safe alternative to reduce the need for second surgical
procedures since they proved to be efficient in preventing the development of infection
and to be replaced by regenerative bone tissue throughout the healing process. Further-
more, the current application and landscape observed in this analysis can be defined as
conservative, from a production process standpoint. Casting and traditional metallurgical
processes are still dominant, as observed, and the authors expect that new technologies
such as additive manufacturing can have a decisive and acute effect on the applications of
biodegradable implants and medical devices. From the design process to the laser sintering
or thermoplastic fusion processes, soon the process-related advantages will be showcased
in literature.

A great number of studies were excluded from the present work for only taking
their experiments in vitro, and most of the included studies carried out their experiments
in animal models, rather than in humans. Thus, future in vivo works, especially those
pertaining to humans, are required to transfer the acquired knowledge on biodegradable implants onto Orthopedics clinical practice.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/bioengineering9080409/s1, Table S1. PRISMA checklist of the systematic search of the relevant studies; Table S2—Risk of bias analysis.

Author Contributions: Conceptualization, J.C.C.P. and S.C.-d.-O.; Methodology, J.C.C.P. and S.C.-d.-O.; Validation, S.C.-d.-O., L.O. and M.F.V.; Data Analysis, J.C.C.P. and S.C.-d.-O.; Original Draft Preparation, J.C.C.P.; Writing—Review & Editing, S.C.-d.-O., L.O. and M.F.V.; Supervision, S.C.-d.-O. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by FCT (Fundaçã o para a Ciência e Tecnologia), within the project PTDC/CTM-CTM/3354/2021 “Biodegradable implants in porous iron obtained by additive manufacturing” and by national funds through FCT Fundação para a Ciência e a Tecnologia, I.P., within the scope of the project RISE-ILA/P/0053/2020. MFV also acknowledges FCT, through IDMEC, under LAETA, Project UIDB/50022/2020.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

(V-) BHA—(Vancomycin-loaded) Bone-like hydroxyapatite/poly(amino acid); Ag/n-HA/PU—Nano-hydroxyapatite combined with a polyurethane containing silver; AgNPs—Silver nanoparticles; AHRG (AgNPs-nHA@RGO)—AgNP-loaded nHA@RGO 3D scaffolds; Al—Aluminum; AMPs—Antimicrobial peptides; ANDB—Antibiotic-eluting Nanofiber-loaded Deproteinized Bone; AZ91—Mg-9%Al-1%Zn; β-TCP—β-Tricalcium Phosphate; BCP—Biphasic-Calcium Phosphate; Bio-Oss®—Demineralized autologous graft bone; BS—Bare composite Scaffolds; BV/TV—Bone volume fraction (is the volume of mineralised bone per unit volume of the sample); CaP—Calcium Phosphate; CFU—Colony-Forming Units; CMC—Carboxymethyl Cellulose; CoNS—Coagulase-negative Staphylococci; cpTi—commercially pure Titanium; CPX—Ciprofloxacin; Cu—Copper; DBP—Decellularized Bovine Bone Particles; DPB—Deproteinized Bovine cancellous Bone; EPS—Extracellular Polymeric Substance; Ga—Gallium; HA—Hydroxyapatite; IAI—Implant-associated infection; IBMs—Infected Bone Defects; IMs—Implantable Matrices; JDBM—3D-printed Mg-Nd-Zn-Zr implant; K20/(100)—Degradable Polyurethane, Hydroxyapatite and Deproteinized Bovine Bone particles (loaded with vancomycin 100mg/mL); Lev—Levofloxacin; LPC—Large pore size 250-350µm; Mg—Magnesium; MRI—Magnetic Resonance Imaging; MRSA—Methicillin-Resistant Staphylococcus aureus; MSNs—Mesoporous Silica Nanoparticles; NaCl—sodium chloride—a pore forming agent (porogen); NanoHA OR n-HA—Nanohydroxyapatite; Nd—Neodymium; NDB—Nanofiber-loaded Deproteinized Bone; NPC—Non-porous coat; P3HB—Poly-3-hydroxybutyrate; PAA—Poly(amino acid) - polymer of six amino acids, containing 6-aminocaproic acid, glycine, L-alanine, L-phenylalanine, L-proline and L-lysine; PBS—Phosphate-Buffered Saline; PCL—Polycaprolactone; PEG 400—Poly(ethylene glycol); PLDLA—Poly-L-D-Lactic Acid; PLGA—Poly (DL-lactic acid-co-glycolic acid); PLLA—Poly-L-lactic Acid; PSI10—Antimicrobial peptide RRWPPWPPRR-NH2; PU—Polyurethane; RGO—Reduced Graphene Oxide; SA-V5(15)—Scaffold absorbed with 5(15) wt% vancomycin (after the development of the scaffold); SBF—Simulated body fluid; Se—Selenium; SE-V5(15)—Scaffold entrapped with 5(15) wt% vancomycin (during scaffold synthesis); Sn—Tin; SPC—Porous coat of small pore size 150–250 µm; Sr—Strontium; Tb,N—Trabecular number; Tb,Sp—Trabecular spacing; UMAO—Ultrasonic Micro-Arc Oxidation; (V-) BHA—(Vancomycin-loaded) Bone-like hy-
droxyapatite/poly(amino acid); Zn—Zinc; Zn-2Cu—Alloy of Zinc and Cu mass ratios of 2wt%; Zr—Zirconium.

References
1. Lew, D.P.; Waldvogel, F.A. Osteomyelitis. Lancet 2004, 364, 369–379. [CrossRef]
2. Kavanagh, N.; Ryan, E.J.; Widaa, A.; Sexton, G.; Fennell, J.; O’Rourke, S.; Cahill, K.C.; Kearney, C.J.; O’Brien, F.J.; Kerrigan, S.W. Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions. Clin. Microbiol. Rev. 2018, 31, e00084-17. [CrossRef] [PubMed]
3. Richards, J.E.; Kauffmann, R.M.; Obremskey, W.T.; May, A.K. Stress-induced hyperglycemia as a risk factor for surgical-site infection in nondiabetic orthopedic trauma patients admitted to the intensive care unit. J. Orthop. Trauma 2013, 27, 16–21. [CrossRef] [PubMed]
4. Patzakis, M.J.; Wilkins, J. Factors influencing infection rate in open fracture wounds. Clin. Orthop. Relat. Res. 1989, 36–40. [CrossRef]
5. Metsemakers, W.J.; Onsea, J.; Neutjens, E.; Steffens, E.; Schuermans, A.; McNally, M.; Nijs, S. Prevention of fracture-related infection: A multidisciplinary care package. Int. Orthop. 2017, 41, 2457–2469. [CrossRef]
6. Metsemakers, W.J.; Kuehl, R.; Moriarty, T.F.; Richards, R.G.; Verhofstad, M.H.J.; Borens, O.; Kates, S.; Morgenstern, M. Infection after fracture fixation: Current surgical and microbiological concepts. Injury 2018, 49, 511–522. [CrossRef]
7. Kotram, K.; Beztarostiti, H.; Metsemakers, W.J.; Raschke, M.J.; Van Lieshout, E.M.M.; Verhofstad, M.H.J. Risk factors for infectious complications after open fractures; a systematic review and meta-analysis. Int. Orthop. 2017, 41, 1965–1982. [CrossRef]
8. Zalavras, C.G. Prevention of Infection in Open Fractures. Infect. Dis. Clin. N. Am. 2017, 31, 339–352. [CrossRef]
9. Gustilo, R.B.; Gruninger, R.P.; Davis, T. Classification of type III (severe) open fractures relative to treatment and results. Orthopedics 1987, 10, 1781–1788.
10. Yim, G.H.; Hardwicke, J.T. The Evolution and Interpretation of the Gustilo and Anderson Classification. J. Bone Joint Surg. Am. 2018, 100, e152. [CrossRef]
11. Puetzler, J.; Zalavras, C.; Moriarty, T.F.; Verhofstad, M.H.J.; Kates, S.L.; Raschke, M.J.; Rosslenbroich, S.; Metsemakers, W.J. Clinical practice in prevention of fracture-related infection: An international survey among 1197 orthopaedic trauma surgeons. Injury 2019, 50, 1208–1215. [CrossRef]
12. Jansen, B.; Peters, G. Foreign body associated infection. J. Antimicrob. Chemother. 1993, 32 (Suppl. A), 69–75. [CrossRef]
13. Wolcott, R.D.; Ehrlich, G.D. Biofilms and chronic infections. JAMA 1999, 282, 2682–2684. [CrossRef]
14. Hedrick, T.L.; Adams, J.D.; Sawyer, R.G. Implant-associated infections: An overview. J. Long-Term Eff. Med. Implants 2006, 16, 83–99. [CrossRef]
15. Ryder, M.A. Catheter-related infections: It’s all about biofilm. Top. Adv. Pract. Nurs. cl. 2005, 5, 1–6.
16. Cook, G.E.; Markel, D.C.; Ren, W.; Webb, L.X.; McKee, M.D.; Schemitsch, E.H. Infection in Orthopaedics. J. Orthop. Trauma 2015, 29 (Suppl. 12), S19–S23. [CrossRef]
17. Lemming, H.C.; Wingender, J.; Szewzyk, U.; Steinberg, P.; Rice, S.A.; Kjellegberg, S. Biofilms: An emergent form of bacterial life. Nat. Rev. Microbiol. 2016, 14, 563–575. [CrossRef]
18. Dudareva, M.; Hotchen, A.J.; Ferguson, J.; Hodgson, S.; Scarborough, M.; Atkins, B.L.; McNally, M.A. The microbiology of chronic osteomyelitis: Changes over ten years. J. Infect. 2019, 79, 189–198. [CrossRef]
19. Ma, X.; Han, S.; Ma, J.; Chen, X.; Bai, W.; Yan, W.; Wang, K. Epidemiology, microbiology and therapeutic consequences of chronic osteomyelitis in northern China: A retrospective analysis of 255 Patients. Sci. Rep. 2018, 8, 14895. [CrossRef]
20. Kuehl, R.; Tschudin-Sutter, S.; Morgenstern, M.; Dangel, M.; Egli, A.; Nowakowski, A.; Suhm, N.; Theilacker, C.; Widmer, A.F. Time-dependent differences in management and microbiology of orthopaedic internal fixation-associated infections: An observational prospective study with 229 patients. Clin. Microbiol. Infect. 2019, 25, 76–81. [CrossRef]
21. Chambers, H.F.; Deleo, F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 2009, 7, 629–641. [CrossRef] [PubMed]
22. Guo, Y.; Song, G.; Sun, M.; Wang, J.; Wang, Y. Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus. Front. Cell. Infect. Microbiol. 2020, 10, 107. [CrossRef] [PubMed]
23. Teterycz, D.; Ferry, T.; Lew, D.; Stern, R.; Assal, M.; Hoffmeyer, P.; Bernard, L.; Uçay, I. Outcome of orthopedic implant infections due to different staphylococci. Int. J. Infect. Dis. 2010, 14, e913–e918. [CrossRef] [PubMed]
24. Cho, O.H.; Bae, I.G.; Moon, S.M.; Park, S.Y.; Kwak, Y.G.; Kim, B.N.; Yu, S.N.; Jeon, M.H.; Kim, T.; Choo, E.J.; et al. Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus: A retrospective observational study. Medicine 2018, 97, e12629. [CrossRef]
25. Van Hengel, I.A.J.; Tierolf, M.; Fratila-Apachitei, L.E.; Apachitei, I.; Zadpoor, A.A. Antibacterial Titanium Implants Biofunctionalized by Plasma Electrolytic Oxidation with Silver, Zinc, and Copper: A Systematic Review. Int. J. Mol. Sci. 2021, 22, 3800. [CrossRef]
26. Tande, A.J.; Patel, R. Prosthetic joint infection. Clin. Microbiol. Rev. 2014, 27, 302–345. [CrossRef]
27. Tattrup, M.; Bue, M.; Koch, J.; Jensen, L.K.; Hanberg, P.; Aalbak, B.; Fuursted, K.; Jensen, H.E.; Søballe, K. Effects of Implant-Associated Osteomyelitis on Cefuroxime Bone Pharmacokinetics: Assessment in a Porcine Model. J. Bone Joint Surg. Am. 2016, 98, 363–369. [CrossRef]

28. Emslie, K.R.; Fenner, L.M.; Nade, S.M. Acute haematogenous osteomyelitis: II. The effect of a metaphyseal abscess on the surrounding blood supply. J. Pathol. 1984, 142, 129–134. [CrossRef]

29. Liu, L.; Webster, T.J. Nanotechnology for reducing orthopedic implant infections: Synthesis, characterization, and properties. In Orthopedic Biomaterials; Springer: Cham, Switzerland, 2017; pp. 31–62. [CrossRef]

30. Berkes, M.; Obremskey, W.T.; Scannell, B.; Ellington, J.K.; Hymes, R.A.; Bosse, M. Maintenance of hardware after early postoperative infection following fracture internal fixation. J. Bone Jt. Surg. Am. 2010, 92, 823–828. [CrossRef]

31. Zimmerli, W. Clinical presentation and treatment of orthopaedic implant-associated infection. J. Intern. Med. 2014, 276, 111–119. [CrossRef]

32. Kapoor, S.K.; Thiyam, R. Management of infection following reconstruction in bone tumors. J. Clin. Orthop. Trauma 2015, 6, 244–251. [CrossRef]

33. Noimark, S.; Dunnill, C.W.; Wilson, M.; Parkin, I.P. The role of surfaces in catheter-associated infections. Chem. Soc. Rev. 2009, 38, 3435–3448. [CrossRef]

34. Lerner, R.K.; Esterhai, J.L., Jr.; Polomano, R.C.; Cheatle, M.D.; Heppenstall, R.B. Quality of life assessment of patients with posttraumatic fracture nonunion, chronic refractory osteomyelitis, and lower-extremity amputation. Clin. Orthop. Relat. Res. 1993, 295, 28–36. [CrossRef]

35. Tribble, D.R.; Conger, N.G.; Fraser, S.; Gleeson, T.D.; Wilkins, K.; Antonuille, T.; Heppenstall, R.B.; Li, P.; et al. Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: Trauma infectious disease outcome study. J. Trauma 2011, 71, S33–S42. [CrossRef]

36. Espirito, J.; Meier, M.; Seitz, J.M. The current performance of biodegradable magnesium-based implants in magnetic resonance imaging: A review. Biom. Mater. 2021, 6, 4360–4367. [CrossRef]

37. Grainger, D.W. All charged up about implanted biomaterials. Nat. Biotechnol. 2013, 31, 507–509. [CrossRef]

38. Saini, M.; Singh, Y.; Arora, P.; Arora, V.; Jain, K. Implant biomaterials: A comprehensive review. World J. Clin. Cases 2015, 3, 52–57. [CrossRef]

39. Mucha, M.; Tylman, M. Novel technique of polymer composite preparation for bone implants. In Advanced Materials Research; Trans Tech Publications Ltd.: Bäch, Switzerland, 2012; pp. 681–685. [CrossRef]

40. Prasad, A.; Bhasney, S.; Katiyar, V.; Sankar, M.R. Biowastes processed hydroxyapatite filled poly (lactic acid) bio-composite for open reduction internal fixation of small bones. Mater. Today Proc. 2017, 4, 10153–10157. [CrossRef]

41. Regar, E.; Sianos, G.; Serruys, P.W. Stent development and local drug delivery. J. Endourol. 2001, 15, 227–248. [CrossRef]

42. Domb, A.J.; Khan, W. Focal Controlled Drug Delivery; Springer: Berlin/Heidelberg, Germany, 2014.

43. Scarno, A.; de Oliveira, P.S.; Traini, T.; Lorusso, F. Sinus Membrane Elevation with Heterologous Cortical Lamina: A Randomized Study of a New Surgical Technique for Maxillary Sinus Floor Augmentation without Bone Graft. Materials 2018, 11, 1457. [CrossRef]

44. Mucha, M.; Tylman, M. Novel technique of polymer composite preparation for bone implants. In Advanced Materials Research; Trans Tech Publications Ltd.: Bäch, Switzerland, 2012; pp. 681–685. [CrossRef]

45. Gotman, I. Characteristics of metals used in implants. J. Endourol. 1997, 11, 383–389. [CrossRef]

46. Prasad, A. Bioabsorbable polymeric materials for biofilms and other biomedical applications: Recent and future trends. Mater. Today Proc. 2021, 44, 2447–2453. [CrossRef]

47. Ibrahim, A.M.; Koolen, P.G.; Kim, K.; Perrone, G.S.; Kaplan, D.L.; Lin, S.J. Absorbable biologically based internal fixation. Clin. Pediatr. Med. Surg. 2015, 32, 61–72. [CrossRef]

48. Teo, A.J.; Mishra, A.; Park, I.; Kim, Y.-J.; Park, W.-T.; Yoon, Y.-J. Polymeric biomaterials for medical implants and devices. ACS Biomater. Sci. Eng. 2016, 2, 454–472. [CrossRef]

49. Adeosun, S.O.; Lawal, G.I.; Gbenebor, O.P. Characteristics of Biodegradable Implants; University of Lagos: Lagos, Nigeria, 2014.

50. Gogolewski, S. Bioresorbable polymers in trauma and bone surgery. J. Intern. Med. 2007, 261, 160–166. [CrossRef]

51. Eberli, D. Tissue Engineering; BoD—Books on Demand: Norderstedt, Germany, 2010.

52. Andreiotelli, M.; Wenz, H.J.; Kohal, R.J. Are ceramic implants a viable alternative to titanium implants? A systematic literature review. Clin. Oral Implant. Res. 2009, 20, 32–47. [CrossRef]

53. Al-Sanabani, J.S.; Madfa, A.A.; Al-Sanabani, F.A. Application of calcium phosphate materials in dentistry. Int. J. Biomater. 2013, 2013, 876132. [CrossRef]

54. Anderson, J.M.; Rodriguez, A.; Chang, D.T. Foreign body reaction to biomaterials. In Seminars in ImmunologyAcademic Press: Cambridge, MA, USA, 2008; pp. 86–100. [CrossRef]

55. Von Eiff, C.; Jansen, B.; Kohnen, W.; Becker, K. Infections associated with medical devices. Drugs 2005, 65, 179–214. [CrossRef]

56. Klevens, R.M.; Edwards, J.R.; Richards, C.L., Jr.; Horan, T.C.; Gaynes, R.P.; Pollock, D.A.; Cardo, D.M. Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep. 2007, 122, 160–166. [CrossRef]

57. Inzana, J.A.; Schwarz, E.M.; Kates, S.L.; Awad, H.A. Biomaterials approaches to treating implant-associated osteomyelitis. Biomaterials 2016, 81, 58–71. [CrossRef] [PubMed]

58. Chen, R.R.; Mooney, D.J. Polymeric growth factor delivery strategies for tissue engineering. Pharm. Res. 2003, 20, 1103–1112. [CrossRef] [PubMed]
59. Le Nihouannen, D.; Hacking, S.A.; Gbureck, U.; Komarova, S.V.; Barralet, J.E. The use of RANKL-coated brushite cement to stimulate bone remodelling. *Biomaterials* **2008**, *29*, 3253–3259. [CrossRef] [PubMed]

60. Nyska, A.; Schiffrinbauer, Y.S.; Brami, C.T.; Maronpot, R.R.; Ramot, Y. Histopathology of biodegradable polymers: Challenges in interpretation and the use of a novel compact MRI for biocompatibility evaluation. *Polym. Adv. Technol.* **2014**, *25*, 461–467. [CrossRef]

61. Ramot, Y.; Haim-Zada, M.; Domb, A.J.; Nyska, A. Biocompatibility and safety of PLA and its copolymers. *Adv. Drug Deliv. Rev.* **2016**, *107*, 153–162. [CrossRef]

62. Ramot, Y.; Nyska, A.; Markovitz, E.; Dekel, A.; Klaiman, G.; Zada, M.H.; Domb, A.J.; Maronpot, R.R. Long-term local and systemic safety of poly (l-lactide-co-epsilon-caprolactone) after subcutaneous and intra-articular implantation in rats. *Toxicol. Pathol.* **2015**, *43*, 1127–1140. [CrossRef]

63. Ramot, Y.; Touitou, D.; Levin, G.; Ickowicz, D.E.; Zada, M.H.; Abbas, R.; Yankelson, L.; Domb, A.J.; Nyska, A. Interspecies differences in reaction to a biodegradable subcutaneous tissue filler: Severe inflammatory granulomatous reaction in the Sinclair minipig. *Toxicol. Pathol.* **2015**, *43*, 267–271. [CrossRef]

64. Rousselle, S.D.; Ramot, Y.; Nyska, A.J.; Comfort, N.D. Pathology of bioabsorbable implants in preclinical studies. *Toxicol. Pathol.* **2019**, *47*, 358–378. [CrossRef]

65. Higgins, J.P.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) *Cochrane Handbook for Systematic Reviews of Interventions*, 2nd ed.; John Wiley & Sons: Hoboken, NJ, USA, 2019.

66. Higgins, J.P.; McKenzie, J.E.; Briel, M.; Devereaux, P.; Dauphinais, R.; Qu, H.; Takesue, S.; Wu, P.; Ad Hoc Group for GRADE Working Group. GRADE guidelines: A new tool for the development of recommendations. *J. Clin. Epidemiol.* **2015**, *68*, 1477–1480. [CrossRef]

67. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan—a web and mobile app for systematic reviews. *Syst. Rev.* **2016**, *5*, 210. [CrossRef]

68. Song, J.; Jin, P.; Li, M.; Liu, J.; Wu, D.; Yao, H.; Wang, J. Antibacterial properties and biocompatibility in vivo and vitro of composite coating of pure magnesium ultrasonic micro-arc oxidation phytic acid copper loaded. *J. Mater. Sci. Mater. Med.* **2019**, *30*, 49. [CrossRef]

69. Li, Y.; Liu, L.; Pan, P.; Zhai, Z.; Mao, Z.; Ouyang, Z.; Yu, D.; Sun, Q.; Tan, L.; Ren, L.; et al. Biodegradable Mg-Cu alloy implants with antibacterial activity for the treatment of osteomyelitis: In vitro and in vivo evaluations. *Biomaterials* **2016**, *106*, 250–263. [CrossRef]

70. Qu, X.; Yang, H.; Jia, B.; Wang, M.; Yue, B.; Zheng, Y.; Dai, K. Zinc alloy-based bone internal fixation screw with antibacterial and anti-osteolytic properties. *Bioact. Mater.* **2021**, *6*, 4607–4624. [CrossRef]

71. Dumlao, P.I.; Paner, N.; Bathan, L.; Lim, B.A. Delayed onset bioabsorbable screw reaction, intact screw extrusion and Pseudomonas aeruginosa tibial tunnel osteomyelitis years after arthroscopic anterior cruciate ligament reconstruction using hamstring graft. *BMJ Case Rep.* **2019**, *12*, e229927. [CrossRef]

72. May, H.; Alper Kati, Y.; Gumussuyu, G.; Yunus Emre, T.; Unal, M.; Kose, O. Bioabsorbable magnesium screw versus conventional titanium screw fixation for medial malleolar fractures. *J. Orthop. Traumatol.* **2020**, *21*, 9. [CrossRef]

73. Brooks, E.K.; Ahn, R.; Tobias, M.E.; Hansen, L.A.; Luke-Marshall, N.R.; Wild, L.; Camagnanari, A.A.; Ehrensberger, M.T. Magnesium alloy AZ91 exhibits antimicrobial properties in vitro but not in vivo. *J. Biomed. Mater. Res. B Appl. Biomater.* **2018**, *106*, 221–227. [CrossRef]

74. Gao, Z.; Song, M.; Liu, R.L.; Shen, Y.; Ward, L.; Cole, I.; Chen, X.B.; Liu, X. Improving in vitro and in vivo antibacterial functionality of Mg alloys through micro-aging by Sr and Ga. *Mater. Sci. Eng. C Mater. Biol. Appl.* **2019**, *104*, 109926. [CrossRef]

75. Qu, X.; Yang, H.; Jia, B.; Yu, Z.; Zheng, Y.; Dai, K. Biodegradable Zn-Cu alloys show antibacterial activity against MRSA bone infection by inhibiting pathogen adhesion and biofilm formation. *Acta Biomater.* **2020**, *117*, 400–417. [CrossRef]

76. Tian, J.; Shen, S.; Zhou, C.; Dang, X.; Jiao, Y.; Li, L.; Ding, S. Investigation of the antimicrobial activity and biocompatibility of magnesium alloy coated with HA and antimicrobial peptide. *J. Mater. Sci. Mater. Med.* **2015**, *26*, 66. [CrossRef]

77. Zhao, W.; Wang, J.; Weiyang, J.; Qiao, B.; Wang, Y.; Li, Y.; Jiang, D. A novel biodegradable Mg-1Zn-0.5 Sn alloy: Mechanical properties, corrosion behavior, biocompatibility, and antibacterial activity. *J. Magnes. Alloys.* **2020**, *8*, 374–386. [CrossRef]

78. Yu, W.; Chen, D.; Ding, Z.; Qiu, M.; Zhang, Z.; Shen, J.; Zhang, X.; Zhang, S.; He, Y.; Shi, Z. Synergistic effect of a biodegradable Mg–Zn alloy on osteogenic activity and anti-biofilm ability: An in vitro and in vivo study. *RSC Adv.* **2016**, *6*, 45219–45230. [CrossRef]

79. Shishatskaya, E.I.; Kamendov, I.V.; Starosvetsky, S.I.; Vinnik, Y.S.; Markelova, N.N.; Shageev, A.A.; Khorzhevsky, V.A.; Peryanova, O.V.; Shumilova, A.A. An in vitro study of osteoplastic properties of resorbable poly-3-hydroxybutyrate in models of segmental osteotomy and chronic osteomyelitis. *Artif. Cells Nanomed. Biotechnol.* **2014**, *42*, 344–355. [CrossRef] [PubMed]

80. Vaquette, C.; Bock, N.; Tran, P.A. Layered Antimicrobial Selenium Nanoparticle-Calcium Phosphate Coating on 3D Printed Scaffolds Enhanced Bone Formation in Critical Size Defects. *ACS Appl. Mater. Interfaces* **2020**, *12*, 55638–55648. [CrossRef] [PubMed]

81. McLaren, J.S.; White, L.J.; Cox, H.C.; Ashraf, W.; Rahman, C.V.; Blunn, G.W.; Goodship, A.E.; Quirk, R.A.; Shakesheff, K.M.; Bayston, R.; et al. A biodegradable antibiotic-impregnated scaffold to prevent osteomyelitis in a contaminated in vivo bone defect model. *Eur. Cell. Mater.* **2014**, *27*, 332–349. [CrossRef]
Bioengineering 2022, 9, 409

82. Gao, J.; Huang, G.; Liu, G.; Liu, Y.; Chen, Q.; Ren, L.; Chen, C.; Ding, Z. A biodegradable antibiotic-eluting PLGA nanofiber-loaded deproteinized bone for treatment of infected rabbit bone defects. J. Biomater. Appl. 2016, 31, 241–249. [CrossRef]

83. Krishnan, A.G.; Biswas, R.; Menon, D.; Nair, M.B. Biodegradable nanocomposite fibrous scaffold mediated local delivery of vancomycin for the treatment of MRSA infected experimental osteomyelitis. Biomater. Sci. 2020, 8, 2653–2665. [CrossRef]

84. Weng, W.; Li, X.; Nie, W.; Liu, H.; Liu, L.; Huang, J.; Zhou, Q.; He, J.; Su, J.; Dong, Z.; et al. One-Step Preparation of an AgNP-nHA@RGO Three-Dimensional Porous Scaffold and Its Application in Infected Bone Defect Treatment. Int. J. Nanomed. 2020, 15, 5027–5042. [CrossRef]

85. Beenken, K.E.; Campbell, M.J.; Ramiruz, A.M.; Alghazali, K.; Walker, C.M.; Jackson, B.; Griffin, C.; King, W.; Bourdo, S.E.; Rifkin, R.; et al. Evaluation of a bone filler scaffold for local antibiotic delivery to prevent Staphylococcus aureus infection in a contaminated bone defect. Sci. Rep. 2021, 11, 10254. [CrossRef]

86. Zhang, D.; Liu, W.; Wu, X.D.; He, X.; Lin, X.; Wang, H.; Li, J.; Jiang, J.; Huang, W. Efficacy of novel nano-hydroxyapatite/polyurethane composite scaffolds with silver phosphate particles in chronic osteomyelitis. J. Mater. Sci. Mater. Med. 2019, 30, 59. [CrossRef]

87. Wang, Q.; Chen, C.; Liu, W.; He, X.; Zhou, N.; Zhang, D.; Hu, H.; Li, J.; Jiang, J.; Huang, W. Levofloxacin loaded mesoporous silica microspheres/nano-hydroxyapatite/polyurethane composite scaffold for the treatment of chronic osteomyelitis with bone defects. Sci. Rep. 2017, 7, 1–13. [CrossRef]

88. Xie, K.; Wang, N.; Guo, Y.; Zhao, S.; Tan, J.; Wang, L.; Li, G.; Wu, J.; Yang, Y.; Xu, W.; et al. Additively manufactured biodegradable porous magnesium implants for elimination of implant-related infections: An in vitro and in vivo study. Bioact. Mater. 2022, 8, 140–152. [CrossRef]

89. Cao, Z.; Jiang, D.; Yan, L.; Wu, J. In vitro and in vivo osteogenic activity of the novel vancomycin-loaded bone-like hydroxyapatite/poly(amino acid) scaffold. J. Biomater. Appl. 2016, 30, 1566–1577. [CrossRef]

90. Ferreira, M.; Rzhepishevska, O.; Grencho, L.; Malheiros, D.; Gonçalves, L.; Almeida, A.J.; Jordão, L.; Ribeiro, I.A.; Ramstedt, M.; Gomes, P.; et al. Levofloxacin-loaded bone cement delivery system: Highly effective against intracellular bacteria and Staphylococcus aureus biofilms. Int. J. Pharm. 2017, 532, 241–248. [CrossRef]

91. Hanafy, A.F.; Ali, H.S.M.; El Achy, S.N.; Habib, E.E. Dual effect biodegradable ciprofloxacin loaded implantable matrices for osteomyelitis: Controlled release and osteointegration. Drug Dev. Ind. Pharm. 2018, 44, 1023–1033. [CrossRef]

92. Taljancovic, M.S.; Jones, M.D.; Ruth, J.T.; Benjamin, J.B.; Sheppard, J.E.; Hunter, T.B. Fracture fixation. Radiographics 2003, 23, 1569–1590. [CrossRef]

93. Torgersen, S.; Gjerdet, N.R.; Erichsen, E.S.; Bang, G. Metal particles and tissue changes adjacent to miniplates. A retrieval study. Acta Odontol. Scand. 1995, 53, 65–71. [CrossRef]

94. Kannan, M.B. Hydroxyapatite coating on biodegradable magnesium and magnesium-based alloys. In Hydroxyapatite (HAp) for Biomedical Applications; Mucalo, M., Ed.; Woodhead Publishing: Sawston, UK, 2015; pp. 289–306.

95. Li, C.; Guo, C.; Fitzpatrick, V.; Ibrahim, A.; Zwierstra, M.J.; Hanna, P.; Lechtig, A.; Nazarian, A.; Lin, S.J.; Kaplan, D.L. Design of biodegradable, implantable devices towards clinical translation. Nat. Rev. Mater. 2020, 5, 61–81. [CrossRef]

96. Chouirfa, H.; Bouloussa, H.; Mignonne, V.; Falentin-Daudré, C. Review of titanium surface modification techniques and coatings for antibacterial applications. Acta Biomater. 2019, 83, 57–74. [CrossRef]

97. Janbozorgi, M.; Karimi Taheri, K.; Karimi Taheri, A. Microstructural evolution, mechanical properties, and corrosion resistance of a heat-treated Mg alloy for the bio-medical application. J. Magnes. Alloy. 2019, 7, 80–89. [CrossRef]

98. Xu, G.; Zhang, L.; Liu, L.; Du, Y.; Zhang, F.; Xu, K.; Liu, S.; Tan, M.; Jin, Z. Thermodynamic database of multi-component Mg alloys and its application to solidification and heat treatment. J. Magnes. Alloy. 2016, 4, 249–264. [CrossRef]

99. Shen, X.; Hu, Y.; Xu, G.; Chen, W.; Xu, K.; Ran, Q.; Ma, P.; Zhang, Y.; Li, J.; Cai, K. Regulation of the biological functions of osteoblasts and bone formation by Zn-incorporated coating on microrough titanium. ACS Appl. Mater. Interfaces 2014, 6, 16426–16440. [CrossRef]

100. Kozerski, S.; Pawlowski, L.; Jaworski, R.; Roudet, F.; Petit, F. Two zones microstructure of suspension plasma sprayed hydroxyapatite coatings. Surf. Coat. Technol. 2010, 204, 1380–1387. [CrossRef]

101. Liu, G.Y.; Hu, J.-J.; Ding, Z.K.; Wang, C. Bioactive calcium phosphate coating formed on micro-arc oxidized magnesium by chemical deposition. Appl. Surf. Sci. 2011, 257, 2051–2057. [CrossRef]

102. Lu, X.; Zhao, Z.; Leng, Y. Biomimetic calcium phosphate coatings on nitric-acid-treated titanium surfaces. Mater. Sci. Eng. A 2007, 47, 700–708. [CrossRef]

103. Förster, Y.; Rentsch, C.; Schneider, W.; Bernhardt, R.; Simon, J.C.; Woroch, H.; Rammelt, S. Surface modification of implants in long bone. Biomater. 2012, 2, 149–157. [CrossRef]

104. Zasluff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389–395. [CrossRef]

105. Kazemzadeh-Narbat, M.; Noordin, S.; Masi, B.A.; Garbuz, D.S.; Duncan, C.P.; Hancock, R.E.; Wang, R. Drug release and bone growth studies of antimicrobial peptide-loaded calcium phosphate coating on titanium. J. Biomed. Mater. Res. B Appl. Biomater. 2012, 100, 1344–1352. [CrossRef]

106. Kazemzadeh-Narbat, M.; Kindrachuk, J.; Duan, K.; Jansen, H.; Hancock, R.E.; Wang, R. Antimicrobial peptides on calcium phosphate-coated titanium for the prevention of implant-associated infections. Biomaterials 2010, 31, 9519–9526. [CrossRef]

107. Tran, P.A.; O’Brien-Simpson, N.; Reynolds, E.C.; Pantarat, N.; Biswas, D.P.; O’Connor, A.J. Low cytotoxic trace element selenium nanoparticles and their differential antimicrobial properties against S. aureus and E. coli. Nanotechnology 2016, 27, 045101. [CrossRef]
108. Samani, S.; Hossainalipour, S.M.; Tamizifar, M.; Rezaie, H.R. In vitro antibacterial evaluation of sol-gel-derived Zn-, Ag-, and (Zn + Ag)-doped hydroxyapatite coatings against methicillin-resistant Staphylococcus aureus. *J. Biomed. Mater. Res. A* 2013, 101, 222–230. [CrossRef]

109. Brennan, S.A.; Ó Fhoghlú, C.; Devitt, B.M.; O’Mahony, F.J.; Brabazon, D.; Walsh, A. Silver nanoparticles and their orthopaedic applications. *Bone Jt. J.* 2015, 97, 582–589. [CrossRef] [PubMed]

110. Gosheger, G.; Hardes, J.; Ahrens, H.; Streitburger, A.; Buerger, H.; Erren, M.; Gunsel, A.; Kemper, F.H.; Winkelmann, W.; Von Eiff, C. Silver-coated megaendoprostheses in a rabbit model—An analysis of the infection rate and toxicological side effects. *Biomaterials* 2004, 25, 5547–5556. [CrossRef] [PubMed]

111. Nostro, A.; Cellini, L.; Di Giulio, M.; D’Arrigo, M.; Marino, A.; Blanco, A.R.; Favaloro, A.; Cutroneo, G.; Bisignano, G. Effect of alkaline pH on staphylococcal biofilm formation. *APMIS* 2012, 120, 733–742. [CrossRef] [PubMed]

112. Qin, H.; Zhao, Y.; Cheng, M.; Wang, Q.; Wang, Q.; Wang, J.; Jiang, Y.; An, Z.; Zhang, X. Anti-biofilm properties of magnesium metal via alkaline pH. *RSC Adv.* 2015, 5, 21434–21444. [CrossRef] [PubMed]

113. Seo, H.-J.; Cho, Y.-E.; Kim, T.; Shin, H.-I.; Kwun, I.-S. Zinc may increase bone formation through stimulating cell proliferation, alkaline phosphatase activity and collagen synthesis in osteoblastic MC3T3-E1 cells. *Nutr. Res. Pract.* 2010, 4, 356–361. [CrossRef]

114. Wang, X.; Ito, A.; Sogo, Y.; Li, X.; Oyane, A. Zinc-containing apatite layers on external fixation rods promoting cell activity. *Acta Biomater.* 2010, 6, 962–968. [CrossRef]

115. Yusa, K.; Yamamoto, O.; Fukuda, M.; Koyota, S.; Koizumi, Y.; Sugiyama, T. In vitro prominent bone regeneration by release zinc ion from Zn-modified implant. *Biochem. Biophys. Res. Commun.* 2011, 412, 273–278. [CrossRef]

116. Szymarski, P.; Frączek, T.; Markowicz, M.; Mikiciuk-Olasik, E. Development of copper based drugs, radiopharmaceuticals and medical materials. *Biometals* 2012, 25, 1089–1112. [CrossRef]

117. Liu, C.; Ren, Z.; Xu, Y.; Pang, S.; Zhao, X.; Zhao, Y. Biodegradable Magnesium Alloys Developed as Bone Repair Materials: A Review. *Scanning* 2018, 2018, 9216314. [CrossRef]

118. Nabiyouni, M.; Brückner, T.; Zhou, H.; Gbureck, U.; Bhaduri, S.B. Magnesium-based bioceramics in orthopedic applications. *Acta Biomater.* 2018, 66, 23–43. [CrossRef]

119. Ciccone, W.J., 2nd; Motz, C.; Bentley, C.; Tasto, J.P. Bioabsorbable implants in orthopaedics: New developments and clinical applications. *J. Am. Acad. Orthop. Surg.* 2001, 9, 280–288. [CrossRef]

120. Danna, N.R.M.D.; Leuchte, P.M.D. Designing Resorbable Scaffolds for Bone Defects. *Bull. NYU Hosp. Jt. Dis.* 2019, 77, 39–44.

121. Smith, L.L.; Niziolek, P.J.; Haberstroh, K.M.; Nauman, E.A.; Webster, T.J. Decreased fibroblast and increased osteoblast adhesion on nanostructured NaOH-etched PLGA scaffolds. *Int. J. Nanomed.* 2007, 2, 383–388.